U.S. patent application number 12/147612 was filed with the patent office on 2008-11-06 for use of acrp30 globular head to promote increases in muscle mass and muscle differentiation.
This patent application is currently assigned to SERONO GENETICS INSTITUTE S.A.. Invention is credited to Bernard Bihain, Joachim Fruebis, Harvey Lodish, Tsu-Shuen Tsao.
Application Number | 20080274971 12/147612 |
Document ID | / |
Family ID | 26903041 |
Filed Date | 2008-11-06 |
United States Patent
Application |
20080274971 |
Kind Code |
A1 |
Lodish; Harvey ; et
al. |
November 6, 2008 |
Use of ACRP30 Globular Head to Promote Increases in Muscle Mass and
Muscle Differentiation
Abstract
The present invention relates to the field of muscle research,
in particular to the discovery of a compound effective for
increasing muscle mass, muscle cell differentiation, and oxidation
of free fatty acids in muscle, useful in methods of treating
muscle-related diseases and disorders as well as for augmenting
muscle mass in general. The muscle-related diseases or disorders
envisaged to be treated by the methods of the invention include,
but are not limited to, muscular dystrophy, and other conditions
resulting in muscle atrophy or muscle wasting.
Inventors: |
Lodish; Harvey; (Brookline,
MA) ; Fruebis; Joachim; (Redmond, WA) ; Tsao;
Tsu-Shuen; (Sommerville, MA) ; Bihain; Bernard;
(Cancale, FR) |
Correspondence
Address: |
SALIWANCHIK LLOYD & SALIWANCHIK;A PROFESSIONAL ASSOCIATION
PO BOX 142950
GAINESVILLE
FL
32614-2950
US
|
Assignee: |
SERONO GENETICS INSTITUTE
S.A.
Evry
FR
|
Family ID: |
26903041 |
Appl. No.: |
12/147612 |
Filed: |
June 27, 2008 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10296865 |
Jul 31, 2003 |
7405193 |
|
|
PCT/IB01/01126 |
May 22, 2001 |
|
|
|
12147612 |
|
|
|
|
60208251 |
May 31, 2000 |
|
|
|
60239735 |
Oct 11, 2000 |
|
|
|
Current U.S.
Class: |
514/9.4 ;
435/375; 435/377 |
Current CPC
Class: |
C07K 14/78 20130101;
A61P 21/00 20180101; A61K 38/2264 20130101 |
Class at
Publication: |
514/12 ; 435/377;
435/375 |
International
Class: |
A61K 38/00 20060101
A61K038/00; C12N 5/06 20060101 C12N005/06; A61P 21/00 20060101
A61P021/00 |
Claims
1. A method of accelerating muscle cell differentiation, comprising
contacting muscle cells with gOBG3 under conditions wherein said
gOBG3 binds to said cells thereby accelerating differentiation of
said cells.
2. The method of claim 1, wherein said cells are in an
individual.
3. The method of claim 2, wherein said gOBG3 is present in a
pharmaceutical composition.
4. The method of claim 3, wherein said gOBG3 is gApm1.
5. A method of accelerating muscle cell reorganization, comprising
contacting muscle cells with, gOBG3 under conditions wherein said
gOBG3 binds to said cells thereby accelerating reorganization of
said cells.
6. The method of claim 5, wherein said cells are in an
individual.
7. The method of claim 6, wherein said gOBG3 is present in a
pharmaceutical composition.
8. The method of claim 7, wherein said gOBG3 is gApm1.
9. A method of increasing muscle mass in an individual, comprising
contacting muscle cells in said individual with gOBG3 under
conditions wherein said gOBG3 binds to said cells thereby
accelerating the reorganization and differentiation of said cells
and increasing said muscle mass.
10. The method of claim 9, wherein said gOBG3 is present in a
pharmaceutical composition.
11. The method of claim 10, wherein said gOBG3 is gApm1.
12. A method of treating muscle cell disorders in an individual,
comprising contacting muscle cells in said individual with gOBG3
under conditions wherein said gOBG3 binds to said cells thereby
accelerating the reorganization and differentiation of said cells,
and thereby treating said muscle cell disorders.
13. The method of claim 12, wherein said muscle cell disorders are
selected from the group consisting of muscle-related eye disorders,
muscle-related recovery after injuries, muscle-related recovery
after surgery, muscle-related disorders of aging, muscle atrophy,
muscle wasting, and muscular dystrophy.
14. The method of claim 13, wherein said gOBG3 is present in a
pharmaceutical composition.
15. The method of claim 14, wherein said gOBG3 is gApm1.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser.
No. 10/296,865, filed Jul. 31, 2003, which is the national stage of
international application No. PCT/IB01/01126, filed May 22, 2001,
which claims the benefit of U.S. Provisional Application Ser. No.
60/208,251, filed May 31, 2000 and Ser. No. 60/239,735, filed Oct.
11, 2000, the disclosures of which are hereby incorporated by
reference in their entirety, including all figures, tables and
amino acid or nucleic acid sequences.
FIELD OF THE INVENTION
[0002] The present invention relates to the field of muscle
research, in particular to the discovery of a compound effective
for increasing muscle mass, muscle cell differentiation, and
oxidation of free fatty acids in muscle, that should be useful in
methods of treating muscle-related diseases and disorders as well
as for augmenting muscle mass. The muscle-related diseases or
disorders envisaged to be treated by the methods of the invention
include, but are not limited to, muscle-related eye diseases and
disorders, muscle-related recovery after injuries, muscle-related
recovery after surgery, muscle-related disorders of aging, muscular
dystrophy, and other conditions resulting in muscle atrophy.
BACKGROUND OF THE INVENTION
[0003] Acrp30 (also known as AdipoQ) is the murine homolog of the
human Apm1 protein (this class of proteins is generically referred
to as OBG3 herein). The predicted protein structure of Apm1
indicates the presence of: 1) a secreted protein signal peptide, 2)
a region containing collagen repeats, and 3) a globular region
(FIG. 2), which is highly conserved (FIG. 1).
[0004] Acrp30 is a circulating protein that is produced by the
adipose tissue (WO 96/39429 which is hereby incorporated herein in
its entirety including any figures, tables, or drawings). Acrp30
mRNA levels are significantly reduced in adipose tissue from obese
ob/ob mice. Acrp30 expression is greatly increased during adipocyte
differentiation and appears to be regulated by insulin. In
addition, Acrp30 has been shown to reduce postprandial blood lipid
levels, stimulate weight loss, and reduce plasma triglycerides in
normal mice, and to promote the reduction of food intake in
genetically obese mice (PCT Application No. 99/07736 which is
hereby incorporated herein in its entirety including any figures,
tables, or drawings).
[0005] Studies performed using just the globular region of Acrp30,
termed globular Acrp30 (gAcrp30) showed that it effectively reduced
body weight in mice on a high-fat cafeteria diet, as well as
decreased fatty acid levels, decreased triglyceride levels, and
improved glucose turnover in post-prandial tests in mice (See US
Provisional Application No's 60/176,228 and 60/198,087, both of
which are hereby incorporated herein by reference including any
drawings, figures, or tables).
SUMMARY OF THE INVENTION
[0006] Globular OBG3 (gOBG3) has previously been linked with
obesity, both in a murine model where treatment with gAcrp30 was
shown to decrease body weight in mice fed a high fat diet, and in
human subjects where an association between some Apm1 single
nucleotide polymorphisms (SNPs) and obesity was documented. The
instant invention is drawn inter alia to the unexpected effects of
gOBG3 on muscle cells, including increasing the oxidation of free
fatty acid in muscle cells as well as accelerating muscle
re-orientation/re-organization and differentiation.
[0007] In a first aspect, the invention features methods of
accelerating muscle cell differentiation, comprising contacting
muscle cells with gOBG3 thereby accelerating differentiation of the
muscle cells. Preferably the contacting is performed under
conditions such that gOBG3 binds to the muscle cells. Preferably
the muscle cells are present in an individual. Preferably, gOBG3 is
present in a pharmaceutical composition. The pharmaceutical
composition preferably further comprises a pharmaceutically
acceptable diluent. gOBG3 can be provided as a polypeptide or as a
polynucleotide encoding gOBG3. Preferably, gOBG3 is gApm1.
[0008] In a second aspect, the invention features methods of
accelerating muscle cell reorganization, comprising contacting
muscle cells with gOBG3 thereby accelerating reorganization of the
muscle cells. Preferably the muscle cells are present in an
individual. Preferably the contacting is under conditions such that
gOBG3 binds to the muscle cells. Preferably, gOBG3 is present in a
pharmaceutical composition. The pharmaceutical composition
preferably further comprises a pharmaceutically acceptable diluent.
gOBG3 can be provided as a polypeptide or as a polynucleotide
encoding gOBG3. Preferably, gOBG3 is gApm1.
[0009] In a third aspect, the invention features methods of
accelerating muscle repair, comprising contacting muscle cells with
gOBG3 thereby accelerating reorganization and differentiation of
the muscle cells. Preferably the contacting is under conditions
such that gOBG3 binds to the muscle cells. Preferably the muscle
cells are present in an individual. Preferably, gOBG3 is present in
a pharmaceutical composition. The pharmaceutical composition
preferably further comprises a pharmaceutically acceptable diluent.
gOBG3 can be provided as a polypeptide or as a polynucleotide
encoding gOBG3. Preferably, gOBG3 is gApm1.
[0010] In a fourth aspect, the invention features methods of
increasing muscle mass in an individual, comprising contacting
muscle cells in the individual with gOBG3 thereby accelerating the
reorganization and differentiation of the muscle cells and
increasing the muscle mass of the individual. Preferably said
contacting is under conditions wherein gOBG3 binds to muscle cells.
Preferably, gOBG3 is present in a pharmaceutical composition. The
pharmaceutical composition preferably further comprises a
pharmaceutically acceptable diluent. gOBG3 can be provided as a
polypeptide or as a polynucleotide encoding gOBG3. Preferably,
gOBG3 is gApm1.
[0011] In a fifth aspect, the invention features methods of
treating muscle cell disorders in an individual, comprising
contacting muscle cells in the individual with gOBG3 thereby
accelerating the reorganization and differentiation of the muscle
cells, and thereby treating the muscle cell disorders. Preferably
the contacting is under conditions wherein gOBG3 binds to muscle
cells. In preferred embodiments, the muscle cell disorders are
selected from the group consisting of muscle-related eye diseases
and disorders, muscle-related recovery after injuries,
muscle-related recovery after surgery, muscle-related disorders of
aging, muscle atrophy and muscular dystrophy. Preferably, gOBG3 is
present in a pharmaceutical composition. The pharmaceutical
composition preferably further comprises a pharmaceutically
acceptable diluent. gOBG3 can be provided as a polypeptide or as a
polynucleotide encoding gOBG3. Preferably, gOBG3 is gApm1.
DEFINITIONS
[0012] Before describing the invention in greater detail, the
following definitions are set forth to illustrate and define the
meaning and scope of the terms used to describe the invention
herein.
[0013] As used herein, the term "OBG3" refers to any member of the
family of homologous proteins that includes Apm1, the human
homologue, as well as Acrp30 or AdipoQ, the mouse homologue. These
proteins and the polynucleotides encoding them are described in
detail in WO 96/39429 and U.S. Patent applications 60/176,228 and
60/198,087, all of which are hereby incorporated by reference
herein in their entirety including any drawings, figures, or
tables.
[0014] The term "polypeptide" refers to a polymer of amino acids
without regard to the length of the polymer. Thus, peptides,
oligopeptides, and proteins are included within the definition of
polypeptide. This term also does not specify or exclude
post-expression modifications of polypeptides. For example,
polypeptides which include the covalent attachment of glycosyl
groups, acetyl groups, phosphate groups, lipid groups and the like
are expressly encompassed by the term polypeptide. Also included
within the definition are polypeptides which contain one or more
analogs of an amino acid (including, for example, non-naturally
occurring amino acids, amino acids which only occur naturally in an
unrelated biological system, modified amino acids from mammalian
systems etc.), polypeptides with substituted linkages, as well as
other modifications known in the art, both naturally occurring and
non-naturally occurring.
[0015] As used herein, the term "non-human animal" refers to any
non-human vertebrate, birds and more usually mammals, preferably
primates, farm animals such as swine, goats, sheep, donkeys, and
horses, rabbits or rodents, more preferably rats or mice. As used
herein, the term "animal" is used to refer to any vertebrate,
preferably a mammal. Both the terms "animal" and "mammal" expressly
embrace human subjects unless preceded with the term
"non-human".
[0016] The term "individual" as used herein refers to a mammal,
including animals, preferably mice, rats, dogs, cattle, sheep, or
primates, most preferably humans that perceives a need (or for whom
a need is perceived) to accelerate muscle cell differentiation, to
accelerate muscle cell reorganization, or to increase muscle mass.
"Perceives a need" does not necessarily refer to a clinical need,
but may simply be the result of an aesthetic desire to increase
muscle mass, or to facilitate athletic training. An individual can
also be a "patient".
[0017] The term "patient" as used herein refers to a mammal,
including animals, preferably mice, rats, dogs, cattle, sheep, or
primates, most preferably humans that are in need of treatment. The
term "in need of treatment" as used herein refers to a judgment
made by a medical care-provider such as a physician, nurse
practitioner, nurse or the like, that a patient could benefit from
or requires treatment. This judgment is made based on a variety of
factors that are in the realm of the medical care-provider's
expertise, but that include the knowledge that the patient is ill,
or will be ill, as the result of a condition that is treatable by
the compounds of the invention.
[0018] The term "accelerating muscle cell differentiation" as used
herein refers to the ability of compounds of the invention to
decrease the number of hours muscle cell differentiation requires
in the absence of the compound (or alternatively stated, to
increase the process of differentiation). This decrease in hours is
at least 5 hours, preferably at least 10 hours, more preferably at
least 20 hours. Alternatively, accelerating muscle cell
differentiation can refer to the ability of compounds of the
invention to increase the numbers of muscle cells undergoing
differentiation at a given time, compared to the number in the
absence of the compound, or to decrease the amount of apoptosis of
muscle cells compared with the amount of apoptosis at a given time
in the absence of the compound. Muscle cell differentiation can be
determined by visual inspection (Example 1) or through markers of
muscle cell differentiation known in the art, some of which are
described in Shimokawa et al (1998) (Biochem Biophys Res Commun
246:287-292; hereby incorporated herein by reference in its
entirety including drawings, figures, and tables; Example 6).
[0019] The term "accelerating muscle cell reorganization" as used
herein refers to the ability of compounds of the invention to
increase muscle cell reorganization in the presence of the compound
as compared to in its absence. Alternatively, accelerating muscle
cell reorganization can refer to the ability of compounds of the
invention to increase the numbers of muscle cells undergoing
reorganization at a given time, compared to the number in the
absence of the compound. Muscle cell reorganization can be
determined by visual inspection (Example 1).
[0020] The term "increasing muscle mass" as used herein refers to
the ability of compounds of the invention to increase the number of
differentiated muscle cells as compared to the numbers in the
absence of the compound. Muscle cell differentiation can be
determined by visual inspection (Example 1) or through markers of
muscle cell differentiation known in the art, some of which are
described in Shimokawa et al (1998). Increases in muscle mass can
also be determined by measurements of the overall size of a muscle
or the strength of a muscle using techniques well-known in the
art.
[0021] The term "muscle cell disorders" as used herein refers to
disorders where there is a loss of muscle mass, or muscle strength.
These would include muscle atrophy or muscle wasting as the result
of disease or trauma, or malnutrition, for example. In addition,
disorders such as muscle-related eye diseases and disorders,
muscle-related recovery after injuries, muscle-related recovery
after surgery, muscle-related disorders of aging, and muscular
dystrophy are specifically envisioned. Whereas some of these
disorders would require a medical care provider's diagnosis
(muscular dystrophy for example), others would simply require an
individual to detect the change and desire the treatment (some
forms of muscle wasting or muscle atrophy).
[0022] The terms "percentage of sequence identity" and "percentage
homology" are used interchangeably herein to refer to comparisons
among polynucleotides and polypeptides, and are determined by
comparing two optimally aligned sequences over a comparison window,
wherein the portion of the polynucleotide or polypeptide sequence
in the comparison window may comprise additions or deletions (i.e.,
gaps) as compared to the reference sequence (which does not
comprise additions or deletions) for optimal alignment of the two
sequences. The percentage is calculated by determining the number
of positions at which the identical nucleic acid base or amino acid
residue occurs in both sequences to yield the number of matched
positions, dividing the number of matched positions by the total
number of positions in the window of comparison and multiplying the
result by 100 to yield the percentage of sequence identity.
Homology is evaluated using any of the variety of sequence
comparison algorithms and programs known in the art. Such
algorithms and programs include, but are by no means limited to,
TBLASTN, BLASTP, FASTA, TFASTA, and CLUSTALW (Pearson and Lipman,
1988; Altschul et al., 1990; Thompson et al., 1994; Higgins et al.,
1996; Altschul et al., 1990; Altschul et al., 1993). In a
particularly preferred embodiment, protein and nucleic acid
sequence homologies are evaluated using the Basic Local Alignment
Search Tool ("BLAST") which is well known in the art (see, e.g.,
Karlin and Altschul, 1990; Altschul et al., 1990, 1993, 1997). In
particular, five specific BLAST programs are used to perform the
following task:
[0023] (1) BLASTP and BLAST3 compare an amino acid query sequence
against a protein sequence database;
[0024] (2) BLASTN compares a nucleotide query sequence against a
nucleotide sequence database;
[0025] (3) BLASTX compares the six-frame conceptual translation
products of a query nucleotide sequence (both strands) against a
protein sequence database;
[0026] (4) TBLASTN compares a query protein sequence against a
nucleotide sequence database translated in all six reading frames
(both strands); and
[0027] (5) TBLASTX compares the six-frame translations of a
nucleotide query sequence against the six-frame translations of a
nucleotide sequence database.
[0028] The BLAST programs identify homologous sequences by
identifying similar segments, which are referred to herein as
"high-scoring segment pairs," between a query amino or nucleic acid
sequence and a test sequence which is preferably obtained from a
protein or nucleic acid sequence database. High-scoring segment
pairs are preferably identified (i.e., aligned) by means of a
scoring matrix, many of which are known in the art. Preferably, the
scoring matrix used is the BLOSUM62 matrix (Gonnet et al., 1992;
Henikoff and Henikoff, 1993). Less preferably, the PAM or PAM250
matrices may also be used (see, e.g., Schwartz and Dayhoff, eds.,
1978). The BLAST programs evaluate the statistical significance of
all high-scoring segment pairs identified, and preferably selects
those segments which satisfy a user-specified threshold of
significance, such as a user-specified percent homology.
Preferably, the statistical significance of a high-scoring segment
pair is evaluated using the statistical significance formula of
Karlin (see, e.g., Karlin and Altschul, 1990).
[0029] By way of example and not limitation, procedures using
conditions of high stringency are as follows: Prehybridization of
filters containing DNA is carried out for 8 h to overnight at
65.degree. C. in buffer composed of 6.times.SSC, 50 mM Tris-HCl (pH
7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500
.mu.g/mL denatured salmon sperm DNA. Filters are hybridized for 48
h at 65.degree. C., the preferred hybridization temperature, in
prehybridization mixture containing 100 .mu.g/mL denatured salmon
sperm DNA and 5-20.times.10.sup.6 cpm of .sup.32P-labeled probe.
Alternatively, the hybridization step can be performed at
65.degree. C. in the presence of SSC buffer, 1.times.SSC
corresponding to 0.15M NaCl and 0.05 M Na citrate. Subsequently,
filter washes can be done at 37.degree. C. for 1 h in a solution
containing 2.times.SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA,
followed by a wash in 0.1.times.SSC at 50.degree. C. for 45 min.
Alternatively, filter washes can be performed in a solution
containing 2.times.SSC and 0.1% SDS, or 0.5.times.SSC and 0.1% SDS,
or 0.1.times.SSC and 0.1% SDS at 68.degree. C. for 15 minute
intervals. Following the wash steps, the hybridized probes are
detectable by autoradiography. Other conditions of high stringency
may also be used and are well known in the art (Sambrook et al.,
1989 and Ausubel et al., 1989, both of which are hereby
incorporated herein in their entirety including any drawings,
figures, or tables). These hybridization conditions are suitable
for a nucleic acid molecule of about 20 nucleotides in length. The
hybridization conditions described can be adapted according to the
length of the desired nucleic acid, following techniques well known
to the one skilled in the art. The suitable hybridization
conditions may, for example, be adapted according to Hames and
Higgins (1985) or Sambrook et al., (1989).
BRIEF DESCRIPTION OF THE FIGURES
[0030] FIG. 1 shows an alignment of the sequences of the human
(APM1), and mouse (adipoQ and acrp30) OBG3 proteins.
[0031] FIG. 2 shows a schematic drawing of the protein structure of
APM1. The putative signal sequence at the N-terminus (AA 1-15), the
unique region (AA 16-42), the collagen region (AA 43-107), and the
globular region (AA 108-244) at the carboxy terminus are shown. Two
protease cleavage sites at AA 100 and AA 131 are also shown.
[0032] FIG. 3 shows a graphical representation of the effect of the
addition of gACRP30 on the oleate oxidation of differentiated C2C12
cells.
[0033] FIG. 4 shows a graphical representation of the effect of
gAcrp30 treatment on fatty acid metabolism in muscle isolated from
mice. EDL and Soleus muscles were isolated from both legs of each
mouse (n=18). One muscle of each pair was incubated in medium with
2.5 .mu.g/mL gAcrp30 (dark gray) and one in medium without gAcrp30
(control-light gray).
[0034] FIGS. 5A and 5B show graphical representations of the effect
of gAcrp30 treatment on triglyceride content of muscle and liver
isolated from mice. Mice that had received 25 .mu.g of gAcrp30
twice daily showed significantly higher (p=0.002) muscle
triglyceride content (FIG. 5A) than those receiving saline
(control: light gray; gAcrp30: dark gray). This contrasted with a
lack of increase in liver triglycerides (FIG. 5B).
[0035] FIGS. 6A and 6B show SDS-PAGE separations of the
purification of Acrp30 and gAcrp30 (6A) and a cleavage product of
apm1 (6B). FIG. 6A, Lane II shows the complete form of Acrp30
purified by FPLC. Lane I shows the proteolytic cleavage product
gAcrp30. FIG. 6B shows a cleavage product of apm-1 after
immunoprecipitation followed by Western blotting. The apparent
molecular weight of this truncated form is 27 kDa, corresponding to
about 70% of the complete form of apm-1 (lane IV). This truncated
form was not detectable when a second anti-serum, specific for the
human non-homologous region (HDQETTTQGPGVLLPLPKGA) of the protein
was used for immunoprecipitation (Lane V) and the same
anti-globular head antiserum for detection. A preimmune serum of
the same animal did not detect any protein; a dimer of apm-1 was
seen with both specific antibodies (apparent MW 74 kDa).
DETAILED DESCRIPTION OF THE INVENTION
[0036] Globular OBG3 has previously been linked with obesity, both
in a murine model where treatment with globular Acrp30 (gAcrp30)
was shown to decrease body weight in mice fed a high fat diet, and
in human subjects where an association between some Apm1 single
nucleotide polymorphisms (SNPs) and obesity was documented. In the
instant application, the inventors have shown inter alia that at
least some of the effects of gOBG3 are directed toward muscle
cells. These effects include increasing the oxidation of free fatty
acid in muscle cells as well as accelerating muscle re-organization
and differentiation. Although the oxidation of free fatty acid in
muscle cells likely is linked to the weight loss previously
observed, it also seems to be linked to the acceleration of muscle
cell reorganization and differentiation.
[0037] The effect of gAcrp30 on muscle cells was assessed using the
murine, skeletal muscle cell line C2C12, and in ex vivo experiments
on muscle cells excised from mice. The C2C12 cells were originally
isolated from normal C3H mouse thigh muscle 72 hours after the
muscle was crushed to increase the yield of mononucleated myogenic
cells and designated C2 cells (Yaffe & Saxel (1977) Nature
270:725-727). The C2C12 cell line is a sub-clone of the C2 cell
line selected for its ability to differentiate rapidly and to
produce extensive contracting myotubes expressing characteristic
muscle proteins (Blau et al (1985) Science 230:758-766). Thus, it
appears that the C2C12 line is probably a clonal derivative of the
satellite muscle cells present in muscle tissue that can replicate
and differentiate to form additional muscle fibers.
[0038] Differentiation of C2C12 myocytes is induced when cultures
are shifted to medium containing low concentrations of mitogens
(Wang & Walsh (1996) Science 273:359-361). During this process
myoblasts withdraw permanently from the cell cycle, express muscle
specific structural proteins, and fuse into multinucleated myotubes
(Davis et al (1987). Extensive cell death is also observed in
cultures of C2C12 cells exposed to differentiation medium
containing 2% horse serum beginning at 24 hours and reaching a
maximum of 20-30% of cells at 48 hours (Wang & Walsh (1996)).
After 72 to 96 hours myotubes become abundant and cell death is
diminished.
[0039] The process of differentiation of the C2C12 cell line is a
good model for studies for treatments of damaged muscle tissue
following muscle injuries associated with strains and sprains, and
tears normally encountered in daily life, as well as during intense
athletic training, or as the result of accidental injury, or
surgery. In all these instances, the muscle tissue is damaged,
needs to re-orient/reorganize, and to grow new muscle fibers. Thus,
treatments that enhance the reorientation/reorganization of the
cultured muscle cells and their differentiation into muscle fibers
should also be useful for accelerating the healing of muscle tissue
following injury, as well as for accelerating the augmentation or
strengthening of muscle cells during physical therapy, or athletic
training.
[0040] Globular Acrp30 was found to induce pronounced
re-orientation/re-organization of undifferentiated C2C12 muscle
cells, as well as to accelerate the process of differentiation into
muscle fibers. Further, there were indications of a decrease in
apoptosis of muscle cells during the differentiation process, since
the numbers of cells compared to the cells not treated with gOBG3
increased. Treatment of differentiated C2C12 cells with gAcrp30
also caused an increase in fatty acid metabolism, since oleate
oxidation was increased approximately 40% (FIG. 3). A significant
increase in oleate oxidation was also seen in ex vivo experiments
with isolated mouse EDL and soleus muscles (FIG. 4), indicating the
strength of the C2C12 cell line as a model system. A concurrent
significant increase in triglyceride concentration was also
observed in the ex vivo muscle.
[0041] Although not wishing to be limited to one hypothesis, the
inventors believe that the increase in metabolism of free fatty
acids that results from the addition of gAcrp30 may be involved in
the acceleration of muscle cell reorientation/reorganization and
differentiation. It is possible that the increase in fatty acid
oxidation provides nutrients or energy that are involved in the
process, or simply sends a signal. Whatever the exact mechanism
involved, it is clear that treatment with gOBG3 has dramatic
effects on muscle cells both in vitro and in vivo, for
re-organization, differentiation and preventing apoptosis. Thus, it
should be useful for treatment of muscle disorders where additional
muscle tissue is desired and potentially where prevention of muscle
cell death is needed. Examples of such disorders include, but are
not limited to, muscle wasting, muscle atrophy, or muscular
dystrophy. Augmenting muscle differentiation and growth should be
ameliorative to the symptoms, if not curative of the disease.
Recruitment of more muscle cells, alignment, and differentiation of
more muscle fibers should have a positive effect, and might at
least prolong the useful life of the muscles of patients afflicted
with muscular dystrophy.
PREFERRED EMBODIMENTS OF THE INVENTION
[0042] I. Muscle-Related Uses of gOBG3
[0043] Methods of Accelerating Muscle Repair:
[0044] The inventors have shown that treatment of muscle cells with
gOBG3 leads to their re-organization and differentiation, as well
as increased free fatty acid oxidation, processes believed to be
important in muscle repair. The muscle cell line used is one
created as the result of trauma to skeletal muscle cells and is
therefore thought to be a good model for studying muscle repair.
Treatments that accelerate muscle cell re-organization, muscle cell
differentiation, and/or muscle cell repair would be useful
following any kind of muscle injury, including, but not limited to
trauma, either accidental, or the result of surgery, or
over-exercising. Trauma to muscles can result from blows, tears,
cuts, strains, etc. gOBG3 variants and fragments, as well as
agonists and antagonists of gOBG3, can be tested for their activity
and thus their potential for use as treatments for the acceleration
of muscle repair using the assays described in the Examples
(particularly Examples 1, 2, 4, 6, 7) or in other assays known to
those in the art.
[0045] Methods of Increasing Muscle Mass:
[0046] In addition to muscle repair, the results of treatment of
muscle cells with gOBG3 suggest that gOBG3 treatment could also be
useful for increasing muscle mass and/or increasing muscle strength
and/or muscle endurance. Increasing body mass (for aesthetic or
sports-related reasons, for example) also involves the recruitment
and development of new muscle cells, which gAcrp30 has been shown
to promote in the experiments with C2C12 cells. Further, increased
free fatty acid oxidation should also be useful in any kind of
endurance or other activities leading to muscle fatigue, since free
fatty acids are a better source of energy and generally less easily
utilized than glucose stores. To some extent, gOBG3 would be
expected to function similarly to the anabolic steroid-type drugs
currently used by athletes. gOBG3 variants and fragments, as well
as agonists and antagonists of gOBG3, can be tested for their
activity and thus their potential for use for increasing muscle
mass, strength and/or endurance using the assays described in the
Examples (particularly Examples 1, 2, 4, 6, 7) or assays known to
those in the art.
[0047] Methods of Treatment of Muscle Disorders:
[0048] For similar reasons as those that suggest gOBG3 would be
useful for accelerating muscle repair and increasing muscle mass,
and additionally because it appears that gOBG3 may be useful in
preventing apoptosis, gOBG3 should also be useful for treating
muscle cell disorders. The muscle cell disorders contemplated are
those that would improve, or whose symptoms would be ameliorated by
treatment with gOBG3. These would include disorders in which the
cells need to be strengthened (improve utilisation of free fatty
acid), or the amount of muscle fibers increased (increased
differentiation of muscle cells). For example, gOBG3 would be
expected to be useful for treating the muscle cell disorders muscle
atrophy, muscle wasting, and muscular dystrophy. Treatment with
gOBG3 is expected to ameliorate some symptoms of these diseases by
increasing the strength of the existing muscle cells by increasing
their use of free fatty acids, and by increasing the
differentiation of additional muscle cells, as well as by
preventing the apoptosis of existing muscle cells. For instance,
even though in muscular dystrophy the existing muscles are abnormal
and their use is gradually lost, it is thought that gOBG3 should be
able to increase the useful life of the muscles. gOBG3 variants and
fragments, as well as agonists and antagonists of gOBG3, can be
tested for their activity and thus their potential for use as
treatments for muscle disorders using the assays described in the
Examples (particularly Examples 1, 2, 4-8) or in other assays known
to those in the art.
II. Globular OBG3 Polypeptides
[0049] Globular OBG3 polypeptides are used in the methods of
treating muscle cells of the instant invention. As used herein, the
term "gOBG3" refers to the globular portion of any member of the
family of homologous proteins that includes Apm1, the human
homologue, as well as Acrp30 or AdipoQ, the mouse homologue.
Globular OBG3 polypeptides have previously been described in detail
in U.S. Provisional patent application Nos. 60/176,228 and
60/198,087, hereby incorporated by reference herein in their
entirety including figures, drawings, or tables. As used herein,
unless specifically limited, the term is meant to include modified
gOBG3 polypeptide sequences, including variants, fragments, analogs
and derivatives of the gOBG3 polypeptides as described
previously.
[0050] For the purposes of this invention, however, useful gOBG3
polypeptides are those that retain any one or more of the desired
activities described herein, including but not limited to the
effects on muscle cells that are the subject of the instant
invention. These include accelerating re-orientation and
differentiation of muscle cells as well as increasing free fatty
acid oxidation, and preventing apoptosis. Variants, fragments,
analogs and derivatives of these polypeptide sequences can be
assayed for their retention of the desired activities using any of
the methods/tests described in Examples 1, 2, and 4-8 or any
comparable assays.
[0051] Globular OBG3 is the portion of intact OBG3 that does not
include the collagen-like tail, or that contains few enough of the
collagen residues such that the peptides do not assemble, or if
they assemble this does not inhibit their activity. Preferably,
this is fewer than 6 collagen residues, fewer than 4, fewer than 2,
or more preferably no collagen residues. By "collagen residues" as
used herein is meant the amino acids glycine, X, Y, where X and Y
can be any amino acid. The collagen-like region of OBG3 is shown in
FIG. 2 for APM1.
[0052] The term "activity" as used herein refers to a measurable
result of the interaction of molecules. For example, a preferred
gOBG3 activity is to accelerate re-orientation of muscle cells,
accelerate differentiation of muscle cells, and/or increase free
fatty acid oxidation of muscle cells. Representative assays to test
for these functions are provided in Examples 1, 2, and 4-9.
However, these examples are provided for explanation, not
limitation. Those with skill in the art would be able to design
other experiments to test for the same retained activity.
[0053] The term the "same retained activity" as used herein refers
to the ability of a variant, fragment, analog or derivative of
gOBG3 to have the same activity as is demonstrated in Examples 1,
2, and 4-8 and claimed in the instant invention. The variant,
fragment, analog or derivative of gOBG3 does not necessarily have
to retain all of the activities described herein for gOBG3's action
on muscle cells, unless specified, but preferably retains at least
one of the activities.
[0054] The "same activity" also relates to the amount of a given
activity observed. In the instant application this refers to the
amount of oleate oxidation, or amount of acceleration of
differentiation, or amount of prevention of apoptosis, for example.
Preferably, the "same" activity as it relates to amount, means
within 10% of the previously observed amount, but it can include a
difference of 20% or 30% or even 50%. However, this is not meant to
limit the use of more effective gOBG3 polypeptides.
[0055] "More effective" gOBG3 polypeptides include those with an
increased activity compared with the gAcrp30 polypeptide used in
experiments described herein. The term "increased" as used herein
refers to the ability of gOBG3 polypeptides to increase an activity
in some measurable way as compared to an appropriate control. As a
result of the presence of a gOBG3 variant, the levels of fatty acid
oxidation, or muscle cell differentiation might increase, or the
amount of apoptosis might decrease, for example, as compared to
appropriate controls, typically the presence of gAcrp30 used in the
experiments described herein. Preferably, an increase in activity
is at least 25%, more preferably at least 50%, most preferably at
least 100%.
[0056] "More effective" gOBG3 polypeptides may also include those
that lack or have a decreased amount of one activity compared with
the gAcrp30 polypeptide used in experiments described herein, and
an increased amount of another activity compared with the gAcrp30
polypeptide used in experiments described herein. The term
"decreased" as used herein refers to the ability of gOBG3
polypeptides to decrease an activity in some measurable way as
compared to an appropriate control, such as the gAcrp30 polypeptide
used in experiments described herein. As a result of the presence
of a gOBG3 variant, fatty acid oxidation might decrease, for
example, as compared to controls in the presence of the gAcrp30
polypeptide used in experiments described herein. Preferably, a
decrease in activity is at least 25%, more preferably at least 50%,
most preferably at least 100%. The term "lack" as used herein
refers to an inability to detect an activity using the methods
described herein, or similar methods. A gOBG3 variant could be
thought to "lack" activity even though an increase of 5 or 10 or
15% of an effect is observed compared with an assay performed in
its absence.
[0057] Finally, "more effective" gOBG3 polypeptides may also
include those that lack or have a decreased amount of one activity
or all activities compared with the gAcrp30 polypeptide used in
experiments described herein, but an increased amount of these
activities in vivo as compared with the gAcrp30 polypeptide used in
experiments described herein.
[0058] Preferred embodiments of the invention feature gOBG3
polypeptide that consists of the sequence of the globular region
shown in FIG. 1, or variants, fragments, analogs, or derivatives
thereof. Preferable embodiments include amino acids 108-244 of SEQ
ID NO:6 or 111-247 of SEQ ID Nos 2 and 4. Alternative preferable
embodiments include amino acids 104 to 247 of the OBG3 proteins
described in FIG. 1.
[0059] In other preferred embodiments, the invention features a
gOBG3 polypeptide comprising at least 115, but not more than 175
contiguous amino acids of any one of the gOBG3 polypeptide
sequences set forth in FIG. 1, wherein no more than 12 of said at
least 115 and no more than 175 contiguous amino acids are present
in the collagen-like region of OBG3. Preferably, the gOBG3
polypeptide comprises at least 125, but not more than 165, or at
least 135, but not more than 155, and no more than 9 are in the
collagen-like region; more preferably at least 125 but not more
than 165, or 135 but not more than 155, and no more than 6 are in
the collagen-like region; or at least 140 and not more than 150,
and no more than 3 are present in the collagen-like region.
Preferably the gOBG3 polypeptide is human or mouse, but most
preferably human.
[0060] Variant gOBG3 polypeptides of the invention may be 1) ones
in which one or more of the amino acid residues are substituted
with a conserved or non-conserved amino acid residue and such
substituted amino acid residue may or may not be one encoded by the
genetic code, or 2) ones in which one or more of the amino acid
residues includes a substituent group, or 3) ones in which a
modified gOBG3 polypeptide is fused with another compound, such as
a compound to increase the half-life of the polypeptide (for
example, polyethylene glycol), or 4) ones in which the additional
amino acids are fused to modify a gOBG3 polypeptide, such as a
leader or secretory sequence or a sequence which is employed for
purification of the modified gOBG3 polypeptide or a pre-protein
sequence. Such variants are deemed to be within the scope of those
skilled in the art. The retention of the desired activity (and thus
desired gOBG3 polypeptides) can be determined using the assays
described in Examples 1, 2, 4-8 or other assays that achieve the
same result.
[0061] Amino acid changes present in a variant polypeptide may be
non-conservative amino acid changes but more preferably are
conservative amino acid changes. In cases where there are one or
more amino acid changes, preferred gOBG3 polypeptides include those
that retain the same activities and activity levels as the
reference gOBG3 polypeptide sequence, as well as those where the
level of one or more activities is increased. Assays for
determining gOBG3 polypeptide activities of the invention are
described herein in the Examples (1, 2, 4-8) in more detail, but
include accelerating muscle differentiation, muscle oleate
oxidation, and decreasing muscle apoptosis, both in vitro and in
vivo.
[0062] In preferred embodiments, the invention features a variant
of a gOBG3 polypeptide that is at least 75% identical to gOBG3
polypeptide sequences selected from the group consisting of
101-244, 108-244, and 132-244 of SEQ ID NO:6, or 104-247, 111-247,
and 135-247 of SEQ ID Nos 2 or 4. Preferably, the amino acid
sequence is at least 85% identical, more preferably 90% identical,
most preferably 95% identical and optionally 100% identical.
Preferably the sequence is human or mouse, and most preferably
human.
[0063] In yet other preferred embodiments, the invention features a
variant of a gOBG3 polypeptide that comprises (or consists of) a
143 contiguous amino acid sequence, wherein at least 100 of the 143
amino acids are identical to amino acids 101-244 of SEQ ID NO:6 or
104-247 of SEQ ID Nos 2 or 4. Preferably, at least 113 of the 143
amino acids are identical, more preferably 127 of the 143 are
identical, even more preferably 134 of the 143 are identical, and
most preferably all of the amino acids are identical. Preferably
the sequence is human or mouse, and most preferably human.
[0064] In yet other preferred embodiments, the invention features a
variant of a gOBG3 polypeptide that comprises (or consists of) a
137 contiguous amino acid sequence, wherein at least 100 of the 137
amino acids are identical to amino acids 108-244 of SEQ ID NO:6 or
111-247 of SEQ ID Nos 2 or 4. Preferably, at least 113 of the 137
amino acids are identical, more preferably 127 of the 137 are
identical, even more preferably 134 of the 137 are identical, and
most preferably all of the amino acids are identical. Preferably
the sequence is human or mouse, and most preferably human.
[0065] In yet other preferred embodiments, the invention features a
variant of a gOBG3 polypeptide that comprises (or consists of) a
113 contiguous amino acid sequence, wherein at least 80 of the 113
amino acids are identical to amino acids 132-244 of SEQ ID NO:6 or
135-247 of SEQ ID Nos 2 or 4. Preferably, at least 90 of the 113
amino acids are identical, more preferably 100 of the 113 are
identical, even more preferably 110 of the 113 are identical, and
most preferably all of the amino acids are identical. Preferably
the sequence is human or mouse, and most preferably human.
[0066] A polypeptide fragment is a polypeptide having a sequence
that is entirely the same as part, but not all, of a given
polypeptide sequence, preferably a gOBG3 polypeptide and variants
thereof. Such fragments may be "free-standing", i.e. not part of or
fused to other polypeptides, or they may be comprised within a
single larger non-OBG3 polypeptide of which they form a part or
region. However, several fragments may be comprised within a single
larger polypeptide. As representative examples of gOBG3 polypeptide
fragments of the invention, there may be mentioned those which have
from about 5, 6, 7, 8, 9 or 10 to 15, 10 to 20, 15 to 40, 30 to 55,
40 to 70, 60 to 95, 80 to 130, or 90 to 144 amino acids long.
Preferred are those fragments containing at least one amino acid
substitution or deletion compared to a gOBG3 polypeptide.
III. Pharmaceutical Compositions
[0067] The gOBG3 polypeptides of the invention can be administered
to a mammal, including a human patient, alone or in pharmaceutical
compositions where they are mixed with suitable carriers or
excipient(s). The pharmaceutical composition is then provided at a
therapeutically or aesthetically effective dose. A therapeutically
or aesthetically effective dose refers to that amount of gOBG3
sufficient to result in amelioration of symptoms of muscle-related
disorders as determined by the methods described herein. A
therapeutically or aesthetically effective dose can also refer to
the amount of gOBG3 necessary for an increase in muscle mass or an
increase in muscle strength or endurance in persons desiring this
affect for aesthetic or athletic reasons alone. A therapeutically
effective dosage of a gOBG3 polypeptide of the invention is that
dosage that is adequate to promote muscle differentiation and/or
increased free fatty acid oxidation, or decreased muscle cell
apoptosis with continued or periodic use or administration.
Techniques for formulation and administration of gOBG3 may be found
in "Remington's Pharmaceutical Sciences," Mack Publishing Co.,
Easton, Pa., latest edition.
[0068] Other diseases or disorders that gOBG3 could be used to
treat or prevent include, but are not limited to, muscle atrophy,
muscle wasting and muscular dystrophy.
[0069] Routes of Administration
[0070] Suitable routes of administration include oral, rectal,
transmucosal, or intestinal administration, parenteral delivery,
including intramuscular, subcutaneous, intramedullary injections,
as well as intrathecal, direct intraventricular, intravenous,
intraperitoneal, intranasal or intraocular injections. A
particularly useful method of administering compounds for promoting
weight loss involves surgical implantation, for example into the
abdominal cavity of the recipient, of a device for delivering gOBG3
over an extended period of time. Sustained release formulations of
the invented medicaments particularly are contemplated.
[0071] Composition/Formulation
[0072] Pharmaceutical compositions and medicaments for use in
accordance with the present invention may be formulated in a
conventional manner using one or more physiologically acceptable
carriers comprising excipients and auxiliaries. Proper formulation
is dependent upon the route of administration chosen.
[0073] Certain of the medicaments described herein will include a
pharmaceutically acceptable carrier and at least one polypeptide
that is a gOBG3 polypeptide of the invention. For injection, the
agents of the invention may be formulated in aqueous solutions,
preferably in physiologically compatible buffers such as Hanks's
solution, Ringer's solution, or physiological saline buffer such as
a phosphate or bicarbonate buffer. For transmucosal administration,
penetrants appropriate to the barrier to be permeated are used in
the formulation. Such penetrants are generally known in the
art.
[0074] Pharmaceutical preparations that can be taken orally include
push-fit capsules made of gelatin, as well as soft, sealed capsules
made of gelatin and a plasticizer, such as glycerol or sorbitol.
The push-fit capsules can contain the active ingredients in
admixture with fillers such as lactose, binders such as starches,
and/or lubricants such as talc or magnesium stearate and,
optionally, stabilizers. In soft capsules, the active compounds may
be dissolved or suspended in suitable liquids, such as fatty oils,
liquid paraffin, or liquid polyethylene glycols. In addition,
stabilizers may be added. All formulations for oral administration
should be in dosages suitable for such administration.
[0075] For buccal administration, the compositions may take the
form of tablets or lozenges formulated in conventional manner.
[0076] For administration by inhalation, the compounds for use
according to the present invention are conveniently delivered in
the form of an aerosol spray presentation from pressurized packs or
a nebulizer, with the use of a suitable gaseous propellant, e.g.,
carbon dioxide. In the case of a pressurized aerosol the dosage
unit may be determined by providing a valve to deliver a metered
amount. Capsules and cartridges of, e.g., gelatin, for use in an
inhaler or insufflator, may be formulated containing a powder mix
of the compound and a suitable powder base such as lactose or
starch.
[0077] The compounds may be formulated for parenteral
administration by injection, e.g., by bolus injection or continuous
infusion. Formulations for injection may be presented in unit
dosage form, e.g., in ampoules or in multi-dose containers, with an
added preservative. The compositions may take such forms as
suspensions, solutions or emulsions in aqueous vehicles, and may
contain formulatory agents such as suspending, stabilizing and/or
dispersing agents.
[0078] Pharmaceutical formulations for parenteral administration
include aqueous solutions of the active compounds in water-soluble
form. Aqueous suspensions may contain substances that increase the
viscosity of the suspension, such as sodium carboxymethyl
cellulose, sorbitol, or dextran. Optionally, the suspension may
also contain suitable stabilizers or agents that increase the
solubility of the compounds to allow for the preparation of highly
concentrated solutions.
[0079] Alternatively, the active ingredient may be in powder or
lyophilized form for constitution with a suitable vehicle, such as
sterile pyrogen-free water, before use.
[0080] In addition to the formulations described previously, the
compounds may also be formulated as a depot preparation. Such long
acting formulations may be administered by implantation (for
example subcutaneously or intramuscularly) or by intramuscular
injection. Thus, for example, the compounds may be formulated with
suitable polymeric or hydrophobic materials (for example as an
emulsion in an acceptable oil) or ion exchange resins, or as
sparingly soluble derivatives, for example, as a sparingly soluble
salt.
[0081] Additionally, the compounds may be delivered using a
sustained-release system, such as semipermeable matrices of solid
hydrophobic polymers containing the therapeutic agent. Various
sustained release materials have been established and are well
known by those skilled in the art. Sustained-release capsules may,
depending on their chemical nature, release the compounds for a few
weeks up to over 100 days.
[0082] Depending on the chemical nature and the biological
stability of the therapeutic reagent, additional strategies for
protein stabilization may be employed.
[0083] The pharmaceutical compositions also may comprise suitable
solid or gel phase carriers or excipients. Examples of such
carriers or excipients include but are not limited to calcium
carbonate, calcium phosphate, various sugars, starches, cellulose
derivatives, gelatin, and polymers such as polyethylene
glycols.
[0084] Effective Dosage
[0085] Pharmaceutical compositions suitable for use in the present
invention include compositions wherein the active ingredients are
contained in an effective amount to achieve their intended purpose.
More specifically, a therapeutically effective amount means an
amount effective to prevent development of or to alleviate the
existing symptoms of the subject being treated. Determination of
the effective amounts is well within the capability of those
skilled in the art, especially in light of the detailed disclosure
provided herein.
[0086] For any compound used in the method of the invention, the
therapeutically effective dose can be estimated initially from cell
culture assays. For example, a dose can be formulated in animal
models to achieve a circulating concentration range that includes
or encompasses a concentration point or range shown to increase
leptin or lipoprotein uptake or binding in an in vitro system. Such
information can be used to more accurately determine useful doses
in humans.
[0087] A therapeutically effective dose refers to that amount of
the compound that results in amelioration of symptoms in a patient.
Toxicity and therapeutic efficacy of such compounds can be
determined by standard pharmaceutical procedures in cell cultures
or experimental animals, e.g., for determining the LD50, (the dose
lethal to 50% of the test population) and the ED50 (the dose
therapeutically effective in 50% of the population). The dose ratio
between toxic and therapeutic effects is the therapeutic index and
it can be expressed as the ratio between LD50 and ED50. Compounds
that exhibit high therapeutic indices are preferred.
[0088] The data obtained from these cell culture assays and animal
studies can be used in formulating a range of dosage for use in
human. The dosage of such compounds lies preferably within a range
of circulating concentrations that include the ED50, with little or
no toxicity. The dosage may vary within this range depending upon
the dosage form employed and the route of administration utilized.
The exact formulation, route of administration and dosage can be
chosen by the individual physician in view of the patient's
condition. (See, e.g. Fingl et al., 1975, in "The Pharmacological
Basis of Therapeutics", Ch. 1).
[0089] Dosage amount and interval may be adjusted individually to
provide plasma levels of the active compound which are sufficient
to maintain the weight loss or prevention of weight gain effects.
Dosages necessary to achieve these effects will depend on
individual characteristics and route of administration.
[0090] Dosage intervals can also be determined using the value for
the minimum effective concentration. Compounds should be
administered using a regimen that maintains plasma levels above the
minimum effective concentration for 10-90% of the time, preferably
between 30-90%; and most preferably between 50-90%. In cases of
local administration or selective uptake, the effective local
concentration of the drug may not be related to plasma
concentration.
[0091] The amount of composition administered will, of course, be
dependent on the subject being treated, on the subject's weight,
the severity of the affliction, the manner of administration and
the judgment of the prescribing physician.
[0092] A preferred dosage range for the amount of a gOBG3
polypeptide of the invention, that can be administered on a daily
or regular basis to achieve desired results, including a reduction
in levels of circulating plasma triglyceride-rich lipoproteins,
range from 0.01-50 mg/kg body mass. A more preferred dosage range
is from 0.02-25 mg/kg. A still more preferred dosage range is from
0.1-20 mg/kg, while the most preferred range is from 0.2-10 mg/kg.
Of course, these daily dosages can be delivered or administered in
small amounts periodically during the course of a day.
EXAMPLES
[0093] Other characteristics and advantages of the invention are
described in the Examples. The following Examples are provided for
illustrative purposes and not as a means of limitation. One of
ordinary skill in the art would be able to design equivalent assays
and methods based on the disclosure herein, all of which form part
of the instant invention.
[0094] Throughout this application, various publications, patents
and published patent applications are cited. The disclosures of
these publications, patents and published patent specifications
referenced in this application are hereby incorporated by reference
into the present disclosure.
Example 1
Effect of gACRP30 Treatment of Muscle cells on Muscle
Differentiation
[0095] C2C12 cells (murine skeletal muscle cell line; ATCC CRL
1772, Rockville, Md.) are seeded sparsely (about 15-20%) in
complete DMEM (w/glutamine, pen/strep, etc)+10% FCS. Two days later
they become 80-90% confluent. At this time, the media is changed to
DMEM+2% horse serum to allow differentiation. The media is changed
daily. Abundant myotube formation occurs after 3-4 days of being in
2% horse serum.
[0096] To test the effect of the presence of gACRP30 on muscle
differentiation, gACRP30 (1 to 2 .mu.g/mL) was added the day after
seeding when the cells are still in DMEM w/10% FCS. Two days after
plating the cells (one day after gACRP30 was first added), at about
80-90% confluency, the media was changed to DMEM+2% horse serum
plus gACRP30.
[0097] The results show that the addition of gACRP30 causes the
cells to begin organizing within one day after its addition. In
contrast to the random orientation of the cells not treated with
gACRP30, those treated with gARCP30 aligned themselves in relation
to each other. In addition, differentiation progressed more rapidly
in the presence o gAcrp30; after only 2 days of gACRP30 treatment
maximal or near maximal differentiation was observed in contrast to
the 3 to 4 days needed in its absence.
Example 2
Effect of gACRP30 on Muscle Cell Fatty Acid Oxidation
[0098] C2C12 cells were differentiated in the presence or absence
of 2 .mu.g/mL gACRP30 for 4 days. On day 4, oleate oxidation rates
were determined by measuring conversion of 1-.sup.14C-oleate (0.2
mM) to .sup.14CO.sub.2 for 90 min. C2C12 cells differentiated in
the presence of gACRP30 undergo 40% more oleate oxidation than
controls differentiated in the absence of oleate (FIG. 3).
[0099] The effect of gAcrp30 on the rate of oleate oxidation was
compared in differentiated C2C12 cells (murine skeletal muscle
cells; ATCC, Manassas, Va. CRL-1772) and in a hepatocyte cell line
(Hepa1-6; ATCC, Manassas, Va. CRL-1830). Cultured cells were
maintained according to manufacturer's instructions.
[0100] The oleate oxidation assay was performed as previously
described (Muoio et al (1999) Biochem J 338:783-791). Briefly,
nearly confluent myocytes were kept in low serum differentiation
media (DMEM, 2.5% Horse serum) for 4 days, at which time formation
of myotubes became maximal. Hepatocytes were kept in the same DMEM
medium supplemented with 10% FCS for 2 days. One hour prior to the
experiment the media was removed and 1 mL of preincubation media
(MEM, 2.5% Horse serum, 3 mM glucose, 4 mM Glutamine, 25 mM Hepes,
1% FFA free BSA, 0.25 mM Oleate, 5 .mu.g/mL gentamycin) was added.
At the start of the oxidation experiment, .sup.14C-Oleic acid (1
.mu.Ci/mL, American Radiolabeled Chemical Inc., St. Louis, Mo.) was
added and cells were incubated for 90 min at 37.degree. C. in the
absence/presence of 2.5 .mu.g/mL gAcrp30. After the incubation
period, 0.75 mL of the media was removed and was assayed for
.sup.14C-oxidation products as described for the muscle FFA
oxidation experiment.
[0101] Oleate oxidation in C2C12 cells determined over 90 min
increased significantly (39%; p=0.036, two-tailed t-Test) in cells
treated with gAcrp30. In contrast, no detectable increase in the
rate of FFA oxidation was seen in hepatocytes incubated with
gAcrp30.
[0102] Triglyceride and Protein Analysis Following Oleate Oxidation
in Cultured Cells
[0103] Following the transfer of media for the oleate oxidation
assay, cells were placed on ice. To determine triglyceride and
protein content, cells were washed with 1 mL of 1.times.PBS to
remove residual media. To each well, 300 .mu.L of cell dissociation
solution (Sigma) was added. Cells were incubated at 37.degree. C.
for 10 min. Plates were tapped to loosen cells, and 0.5 mL of
1.times.PBS was added. The cell suspension was transferred to an
eppendorf tube, each well was rinsed with an additional 0.5 mL of
1.times.PBS, and the rinse was transferred to appropriate eppendorf
tube. Samples were centrifuged at 1000 rpm for 10 minutes at room
temperature. The supernatant was discarded, and 750 .mu.L of
1.times.PBS/2% chaps was added to each cell pellet. The cell
suspension was vortexed and was placed on ice for 1 hour. Samples
were then centrifuged at 13000 rpm for 20 min at 4.degree. C.
Supernatants were transferred to new tubes and frozen at
-20.degree. C. until analyzed.
[0104] The amount of triglycerides in each sample was determined
using Sigma Diagnostics GPO-TRINDER enzymatic kit. The procedure
outlined in the manual was adhered to with the following
exceptions: the assay was performed in a 48 well plate, 350 .mu.L
of sample volume was assayed, the control blank consisted of 350
.mu.L PBS/2% chaps, and the standard contained 10 .mu.L of the
standard provided in the kit plus 690 .mu.L PBS/2% chaps. Analysis
of the samples was performed on a Packard Spectra Count at a
wavelength of 550 nm.
[0105] Protein analysis was carried out on 25 .mu.L of each
supernatant sample using the BCA protein assay (Pierce) following
manufacturer's instructions. Analysis of the samples was performed
on a Packard Spectra Count at a wavelength of 550 nm.
[0106] Triglyceride production in both C2C12 and Hepa 1-6 cells did
not change significantly in the absence/presence of Acrp30 and
gAcrp30. The protein content of all cells analyzed was equivalent
in the absence/presence of Acrp30 and gAcrp30.
Example 3
Production of Recombinant Acrp30
[0107] An illustrative method for producing recombinant OBG3 is
given below. Although the method describes the production of the
mouse analog, Acrp30, a person of ordinary skill in the art would
be able to use the guidance provided to produce other OBG3 analogs,
including but not limited to, the human analog, Apm1.
[0108] Recombinant Acrp30 is cloned in pTRC His B (Invitrogen)
between BamH1 and Xho1 and maintained in E. coli DH5-.alpha.. The
sequence of the Acrp30 insert corresponds to Acrp 30 genbank U37222
bases 88 to 791, except in position 382 where in #3 G replaces A
found in ACRP 30 (V instead of M). The corresponding nucleotide in
AdipoQ U49915 is G as in clone #3. The amino acid V is also
conserved in the human sequence Apm-1 D45371.
Culture:
[0109] Plate out bacteria in LB agar media containing 100 .mu.g/mL
ampicillin. Inoculate 1 colony into 5 mL media (no agar) at
37.degree. C. overnight. Add 2 mL of this initial culture into 500
mL Erlenmeyer flasks containing 200 mL LB media and 100 .mu.g/mL
ampicillin. Incubate at 37.degree. C. in an orbital shaker until
the OD.sub.600=0.2. Add IPTG to a final concentration of 1 mM
(stock solution=1 M). Incubate at 37.degree. C. overnight.
Lysis:
[0110] Pellet the bacteria by centrifugation (Sorvall, 3500 rpm, 15
min, 4.degree. C.) in a pre-weighed tube.
[0111] At 4.degree. C. resuspend the pellet in 3 mL/g of lysis
buffer
[0112] Add 40 .mu.L/g PMSF 10 mM
[0113] Add 80 .mu.L/g of lysozyme 10 mg/mL
[0114] Incubate 20 min on ice, shaking intermittently
[0115] Add 30 .mu.L/g 10% sodium deoxycholate
[0116] Incubate at 37.degree. C. until the lysate is viscous
[0117] Freeze in liquid Nitrogen and thaw at 37.degree. C. three
times
[0118] Sonicate 2.times., 30 sec, 25% cycle, 2.5 power level
[0119] Centrifuge 30 min, 15000 rpm, 4.degree. C.
[0120] Recover the supernatant
[0121] Note: The lysate can be stored frozen before or after the
sonication step.
Batch Purification:
[0122] 1. Pack 1 mL of Probond resin (Invitrogen; 1 mL=2 mL
suspended gel) into a 5 mL column. Wash with 5 mL PBS.
[0123] 2. Apply 5 mL bacterial supernatant to the 1 mL of gel. (If
volume is very high, use several small columns.)
[0124] 3. Wash with 24 mL phosphate buffer, pH 7.8, followed by a
wash with 24 mL phosphate buffer, pH 6.
[0125] 4. Elute with imidazole buffer and collect fractions of 1
mL.
[0126] 5. Analyze fractions by OD at 280 nm or by SDS-PAGE (12.5%;
dilution 1/2 in 2.times. sample buffer) under reducing conditions
(100.degree. C., 5 min)
[0127] 6. Pool the fractions containing protein (usually fraction
numbers 2-4 for concentrations of 0.8-1 mg/mL and fractions 1, 5
and 6 for concentrations of 0.2-0.4 mg/mL).
[0128] 7. Dialyze thoroughly against 1.times.PBS, 24 mM ammonium
bicarbonate or 50 mM Tris, pH 7.4 containing 250 nM NaCl.
Concentrate by Speed-Vac if needed.
[0129] 8. Analyze protein by the Lowry method.
[0130] 9. Aliquot and store at -20.degree. C.
Purification On Liquid Chromatography System
[0131] 1. Pack 5 mL of Probond resin into a 5 mL column.
[0132] 2. Wash with 4 bed volumes of phosphate buffer pH 7.8, 1
mL/min.
[0133] 3. Inject 25 mL lysate (filtered on 0.45.mu. or centrifuged
at 3000 rpm, 30 min, 4.degree. C., Beckman Allegra 6R) at 0.5
mL/min.
[0134] 4. Wash with 4 bed volumes of phosphate buffer, pH 7.8 at 1
mL/min.
[0135] 5. Wash with 12 bed volumes of phosphate buffer pH 5.5 at 1
mL/min.
[0136] 6. Elute bound fraction with phosphate buffer, pH 5.5,
containing 1 M imidazole at 1 mL/min.
[0137] 7. Collect fractions, dialyze and analyze protein as
described for batch purification, steps 7-9.
Example 4
Effect of ACRP30 on Oleate Oxidation in Isolated Muscle
[0138] Intact muscles were isolated from C57BL6/J mice and the
oleate oxidation of the isolated muscle was measured (Clee et al
(2000) J Lipid Res 41:521-531; Muoio et al (1999) Am J Physiol
276:E913-921).--Oleate oxidation in isolated muscle was measured as
previously described (Cuendet et al (1976) J Clin Invest
58:1078-1088; Le Marchand-Brustel (1978) Am J Physiol
234:E348-E358, hereby incorporated by reference herein in its
entirety including any figures, drawings, or tables).
[0139] Two groups of C57BL6/J mice, age 5 and 33 weeks, were used.
Mice were kept on a regular diet with free access to food and
water. The day/night light cycle was kept at 12 hr ON/12 hr OFF.
The older animals were injected twice daily with either saline or
25 .mu.g of gACRP30 for 3-4 days. The younger group of animals was
given a high fat meal (6 g butter, 6 g sunflower oil, 10 g nonfat
dry milk, 10 g sucrose, 12 ml, distilled water prepared fresh) by
gavage (vol.=1% of body weight) at time 0 and was injected with
saline or gACRP30 only at time 0 and again at 45 minutes. They were
sacrificed at 180 minutes. The gACRP30 used was prepared as
described in Example 3.
[0140] After cervical dislocation, soleus and EDL muscles were
rapidly isolated from the hind limbs of the mice. The distal tendon
of each muscle was tied to a piece of suture to facilitate transfer
among different media. All incubations were carried out at
30.degree. C. in 1.5 mL of Krebs-Ringer bicarbonate buffer (118.6
mM NaCl, 4.76 mM KCl, 1.19 mM KH.sub.2PO.sub.4, 1.19 mM MgSO.sub.4,
2.54 mM CaCl.sub.2, 10 mM Hepes, pH7.4) supplemented with 4% bovine
serum albumin, FFA free (fraction V, RIA grade, Sigma, Inc., St.
Louis, Mo.) and 5 mM glucose (Sigma, Inc., St. Louis, Mo.). The
concentration of oleate (Sigma, Inc., St. Louis, Mo.) throughout
the experiment was 0.25 mM. All media were oxygenated (95% O.sub.2;
5% CO.sub.2) prior to incubation. The gas mixture was hydrated
throughout the experiment by bubbling through a gas washer (Kontes
Inc., Vineland, N.J.).
[0141] Muscles were rinsed for 30 min in incubation media with
oxygenation. The muscles were then transferred to fresh media (1.5
mL) and incubated at 30.degree. C. in the presence of 1 .mu.Ci/mL
[1-.sup.14C] oleic acid (ARC) and 1 .mu.Ci/mL [5-.sup.3H]-glucose
(Amersham). The incubation vials containing this media were sealed
with a rubber septum from which a center well carrying a piece of
Whatman paper (1.5 cm.times.11.5 cm) was suspended.
[0142] After an initial incubation period of 10 min with constant
oxygenation, gas circulation was removed to close the system to the
outside environment. The muscles were incubated for an additional
90 min at 30.degree. C. At the end of this period, 0.45 mL of
Solvable (Packard Instruments, Meriden, Conn.) was injected onto
the Whatman paper in the center well. The oxidation of oleate by
the muscle was stopped at this time point by transferring the vial
onto ice.
[0143] After 5 min, the muscle was removed from the medium, was
cleaned of connective tissue, was weighed and was frozen for
further analysis. An aliquot of 0.5 mL medium was removed, the
vials were closed again and 1 mL of 35% perchloric acid was
injected with a syringe into the media by piercing through the
rubber septum with a needle. The CO.sub.2 released from the
acidified media was collected by the Solvable in the center
well.
[0144] After a 90 min collection period at 30.degree. C., the
Whatman paper was removed from the center well and placed in
scintillation vials containing 15 mL of scintillation fluid
(HionicFlour, Packard Instruments, Meriden, Conn.). The amount of
.sup.14C radioactivity was quantitated by liquid scintillation
counting. The rate of oleate oxidation was expressed as nmol oleate
produced in 90 min/g muscle.
[0145] To test the effect of gACRP30 or ACRP30 on oleate oxidation,
these proteins were added to the media at a final concentration of
2.5 .mu.g/mL and maintained in the media throughout the procedure.
Two muscles of different oxidative capacity (soleus and extensor
digitorum longus (EDL)) were tested (FIG. 4). EDL and Soleus
muscles were isolated from both legs of normal C57BL/6J mice
(n=18). One muscle of each pair was incubated in medium with 2.5
.mu.g/ml, gAcrp30 (dark gray) and one in medium without gAcrp30
(control--light gray). This experimental design allowed us to
compare oleate oxidation in pairs of muscles isolated from the same
animal. .sup.14C-Oleate oxidation was determined over 90 minutes.
Incubation of EDL and soleus muscles for 90 minutes in medium
containing 2.5 .mu.g/ml gAcrp30 leads to a statistically
significant increase in oleate oxidation (p<0.05, paired,
one-tailed, t-Test) or (p=0.0041, Repeated Measures Analysis of
Variance, Univariate Tests of Hypotheses for Within Subject
Effects) in both muscle types.
[0146] Both muscle types showed a significant response to gAcrp30.
The relative increase in FFA oxidation was 17% (p=0.03) and 10%
(p=0.04) for EDL and soleus, respectively. In humans, muscles
represent approximately 25% of body weight. Therefore, even a
moderate increase in free fatty acid oxidation can have
quantitatively important consequences on overall energy
utilization.
[0147] In summary, these experiments show that gAcrp30 acts on
muscle cells in vivo and ex vivo. The invention is drawn, inter
alia, to the effects of gAcrp30 on muscle resulting in increased
lean muscle mass and exercise capability. The increase in oleate
oxidation seen in these whole muscle experiments, suggests that
experiments done using the simpler C2C12 cell line model are
predictive for effects in vivo.
[0148] The hindlimb muscle and liver triglyceride content was
measured after gAcrp30 treatment of mice. Hind limb muscles as well
as liver samples were removed from treated and untreated animals
and the triglyceride and free fatty acid concentration was
determined following a standard lipid extraction method
(Shimabukuro et al (1997) Proc Natl Acad Sci USA 94:4637-4641,
hereby incorporated herein by reference in its entirety including
any figures, drawings, or tables) followed by TG and FFA analysis
using standard test kits.
[0149] Short-term treatment of animals with gAcrp30 (2 injections
of 25 .mu.g each given within 3 hours before sacrifice) did not
change the triglyceride content either of hind limb muscle or liver
tissue. However, after 3 days of treatment, during which period
normal C57BL/6J mice consumed a regular rodent diet, mice that had
received 25 .mu.g of gAcrp30 twice daily showed significantly
higher (p=0.002) muscle triglyceride content (FIG. 5A) than those
receiving saline (control: light gray; gAcrp30: dark gray). This
contrasted with a lack of increase in liver triglycerides (FIG.
5B). Furthermore, no detectable increase in muscle TG was observed
after the 16-day treatment shown independently by directly
measuring the muscle TG content and by oil red O staining of frozen
microscope sections. In summary, the data indicate that the
increase in TG content was transient.
[0150] Ketone bodies (KB) are produced in the liver as a result of
free fatty acid oxidation, but KB formation does not occur
significantly in muscle. In mice receiving the high fat test meal
and saline injection, the level of plasma KB increased
significantly over the next 3 hours (183.+-.12%, n=6). Animals
treated with gAcrp30, on the other hand, showed no increase in
plasma KB concentrations. Although not wishing to be limited by any
particular theory, this suggests that gAcrp30 inhibits either
directly KB formation or can decrease KB production by inhibiting
liver FFA oxidation.
Example 5
Methods of Testing the Effect of gOBG3 on Apoptosis
[0151] Prior experiments indicated that gAcrp30 either increased
cell division or decreased apoptosis is C2C12 cells undergoing
differentiation (Example 1). In order to assess the effect C2C12
cells can be transferred into medium containing 0.5% horse serum
(rather than 2% horse serum for differentiation), which rapidly
induces the onset of apoptosis (Wang & Walsh (1996) hereby
incorporated herein by reference in its entirety including any
figures, tables, or drawings). Cells would then be incubated for 16
hours either in the presence or absence of gACRP30 and then the
level of apoptosis compared by staining for ApopTag as described in
Wang & Walsh (1996).
Example 6
Methods of Assessing the Acceleration of Myoblast Differentiation
with gOBG3
[0152] Prior experiments have also indicated that gAcrp30
accelerates re-organization/reorientation and differentiation of
C2C12 muscle cells in vitro (Example 1). Rapid, highly sensitive
methods are available to facilitate screening of the activity of
variants of gAcrp30 (and antagonists and agonists) for their effect
on differentiation. These assays include, among others, a TaqMan
PCR-based method that assesses mRNA levels of muscle-specific
markers of differentiation, including, but not limited to, muscle
regulatory factor, myogen, alpha-actin, thermoregulatory uncoupling
protein (UCP2), glucose transporter isotype glut4, myf5,
beta-actin, UCP1, UCP3, and glut1 (Shimokawa et al (1998) Biochem
Biophys Res Commun 246:287-292, hereby incorporated by reference
herein in its entirety including any figures, drawings, or tables).
Levels of mRNA would be compared between the gAcrp30 treated and
the untreated cultures of differentiating C2C12 cells.
Example 7
Effect of gOBG3 on Muscle Cells In Vivo
[0153] Experiments can be performed on normal mice as well as mice
fed a high fat diet, to assess increases in the differentiation of
muscle cells over a time course of treatment using the TaqMan
PCR-based method described in Example 6, for example. Other muscle
cell parameters discussed herein can also be assessed over time.
The animal experiments can be performed as follows, for
example:
[0154] Experiment 1: 10-week-old male C57BL/6J mice were put on a
very high fat/sucrose purified diet for 19 days to promote weight
gain (see Example 4); the average body weight at this time was 30
g. The mice were then surgically implanted with an osmotic pump
(Alzet, Newark, Del.) delivering either 2.5 .mu.g/day of gAcrp30, 5
.mu.g/day of Acrp30, or physiological saline. The mice were
continued on the high fat diet and their body weight was recorded
over the following 10-day period. Muscle parameters can be assessed
over this same time period.
[0155] Experiment 2: mature 9 month old, male obese C57BL/6J mice
that had been on the same high fat/sucrose diet for 6 months; the
average body weight when the study began was 52.5.+-.0.8 g. Three
groups of 8 mice were treated with saline, Acrp30 or gAcrp30 for 16
days. Animals in the treated group received twice daily 25 .mu.g of
protein subcutaneously. Body weights were recorded at appropriate
time points (daily or weekly). Muscle parameters can also be
assessed over the same time period.
Example 8
Mouse Models of Muscular Dystrophy
[0156] In order to further assess the efficacy of gAcrp30 and
analogs, variants, and fragments thereof (as well as antagonists or
agonists as needed) mouse models of muscular dystrophy can be used
including, but not limited to, 129P1/ReJ-Lama2.sup.dy,
C57BL/10ScSn-Dmd.sup.mdx/J, C57BL/6J-Lama2.sup.dy,
C57BL/6J-Lama2.sup.dy-2J, C57BL/6Ros-Dmd.sup.mdx-2Cv,
C57BL/6Ros-Dmd.sup.mdx-3Cv, C57BL/6Ros-Dmd.sup.mdx-4Cv,
C57BL/6Ros-Dmd.sup.mdx52Cv, and D.B/20Ei-Lama2.sup.dy-6J/+, all of
which are available from Jackson Laboratories. The experiments
would include beginning to treat mice as young as possible (and
then starting at increasingly later time points) with gAcrp30 as
described in Example 7 and comparing the onset and severity of
disease symptoms with untreated mice.
Example 9
Cellular Binding and Uptake of gOBG-3 as Detected by Fluorescence
Microscopy
[0157] Fluorecein isothiocyanate (FITC) conjugation of gOBG3:
Purified gOBG3 at 1 mg/mL concentration was labeled with FITC using
Sigma's FluoroTag FITC conjugation kit (Stock No. FITC-1). Protocol
outlined in the Sigma Handbook for small scale conjugation was
followed for gOBG3 labeling.
[0158] Cell Culture: C2C12 mouse skeletal muscle cells (ATCC,
Manassas, Va. CRL-1772) and Hepa-1-6 mouse hepatocytes (ATCC,
Manassas, Va. CRL-1830) were seeded into 6 well plates at a cell
density of 2.times.10.sup.5 cells per well. C2C12 and Hepa-1-6
cells were cultured according to repository's instructions for
24-48 hours prior to analysis. Assay was performed when cells were
80% confluent.
[0159] FITC labeled gOBG3 cellular binding and uptake using
microscopy in C2C12 and Hepa 1-6 cells. FITC-gOBG3 (50 nM/mL) was
added to each cell culture well. Cells were incubated for 1 hour at
37.degree. C., 5% CO.sub.2. Cells were washed 2.times. with PBS,
cells were scraped from well into 1 mL of PBS. Cell suspension was
transferred to an eppendorf tube and centrifuged at 1000 rpm for 2
minutes. Supernatant was removed and cells resuspended in 200 .mu.L
of PBS. Binding and uptake of FITC-gOBG3 was analyzed by
fluorescence microscopy under 40.times. magnification.
[0160] Analysis of C2C12 and Hepa 1-6 cells reveals identical
phenotypes with respect to FITC-gOBG3 binding and uptake profiles.
FITC-gOBG3 appears to be localized within vesicles in the cytoplasm
of both mouse hepatocytes and mouse myoblasts, suggesting that
binding and uptake of FITC-gOBG3 is occurring. Thus, this assay may
be useful for identifying agents that facilitate or prevent the
uptake and/or binding of OBG3 or gOBG3 polypeptides to cells by
adding the substance to be tested with, before, or after the
FITC-gOBG3.
Example 10
Detection of Apm-1 Fragment in Human Plasma after
Immunoprecipitation
[0161] The recombinant form of Acrp30 protein used has an apparent
molecular weight of 37 kDa and forms a dimer of 74 kDa (FIG. 6 A,
Lane II). A proteolytic fragment that contains the entire globular
head region (gAcrp30) and that migrates with an apparent molecular
weight of 18 kDa was generated using acetylated trypsin (FIG. 6A,
lane I). Both protein preparations (Acrp30 and gAcrp30) were
essentially endotoxin free; "ActiClean Etox" affinity columns were
used to remove potential endotoxin contaminations (Sterogene
Bioseparations Inc., Carlsbad, Calif.) following the manufacturer's
protocol. Endotoxin levels were determined by Endosafe, Charleston,
S.C. As determined by N-terminal sequencing of purified gAcrp30,
the site of cleavage was just before amino acid 104.
[0162] Immunoprecipitation of human plasma Apm followed by Western
blotting was used to detect a cleavage product of Apm-1, the human
homolog of Acrp30, using a globular head specific anti-serum for
the immunoprecipitation step as well as for the detection step.
Preimmune serum or serum raised against the globular head domain or
human non-homologous region (HDQETTTQGPGVLLPLPKGA) were
cross-linked to protein A (Sigma Chemical CO, Saint Louis, Mo.)
using dimethyl-pimelimidate-dihydrochloride (Sigma Chemical Co,
Saint Louis, Mo.). After washing (0.2 M salt), proteins were eluted
from protein A, were separated by SDS-PAGE, and were transferred to
Protran.RTM. pure nitrocellulose membrane (Schleicher and Schuell,
Keene, N.H.) using standard procedures. Apm-1 products were
visualized using globular head domain antibodies labeled with
biotin; horseradish peroxidase conjugated to Streptavidin and
CN/DAB substrate kit (Pierce, Rockford, Ill.) according to
manufacturer's instructions.
[0163] The apparent molecular weight of this truncated form was 27
kDa, corresponding to about 70% of the complete form of Apm-1 (FIG.
6B, Lane IV). This truncated form was not detectable when
immunoprecipitation was performed using a different antibody
directed against the human non-homologous region
(HDQETTTQGPGVLLPLPKGA) of Apm-1; this domain is located toward the
NH.sub.2 terminal end of the protein outside of the globular domain
(FIG. 6, Lane V). Both anti-Apm-1 antibodies directed against
either the globular or the non-globular domain identified the
full-length form of the protein, as well as a low abundance dimer
of apparent MW 74 kDa.
Example 11
Tissue Distribution of gACRP30
[0164] Intra venous Injection of .sup.125I (g)Acrp30
[0165] The disappearance from plasma and subsequent tissue
distribution of Acrp30 and the globular head (gAcrp30) was
investigated by injecting .sup.125I (g)Acrp30 into CD-1 mice.
[0166] CD-1 mice were kept on regular diet with free access to food
and water. The day/night light cycle was kept at 12 hr ON/12 hr
OFF. Acrp30 and gACRP30 were prepared as previously described and
labeled with .sup.125I to a specific activity of approximately 100
cpm/ng using Iodobeads (Pierce). The labeled protein was prepared
immediately before injection and 0.1-0.5 .mu.Ci were injected
through the tail vein. Clearance of the labeled protein from plasma
was followed over 3 hrs after which the animals were perfused
systemically with PBS+EDTA to remove all blood. Tissues were
isolated (liver, adipose, kidney, skeletal muscle, brain), weighed,
and the specific activity in plasma and tissue was determined.
[0167] Acrp30 showed a plasma half-life of about 7 hours. The
plasma turnover of gAcrp30 was significantly faster showing a
half-life close to 1 hour. The majority of the labeled Acrp30
protein was found in kidney and in skeletal muscle tissue,
indicating that it represents a functional target tissue. A much
smaller part of the injected protein was found in adipose and liver
tissue and only a very small pool was seen in brain.
[0168] Immunohistochemistry Studies
[0169] Frozen sections of skeletal muscle from mice were stained
using an antibody to the globular head of Acrp30 coupled with
calorimetric detection. Briefly, C57 mice were sacrificed and
various skeletal muscles were isolated. Muscles were frozen in an
isopentane/liquid nitrogen bath. Tissue was then sectioned at 8
microns using a Leica 3050 cryostat and sections were picked up on
microscope slides. Slides were dried overnight and fixed with
4.degree. C. acetone after which sections were pretreated for
endogenous peroxidase and biotin prior to IHC. An antibody to
gAcrp30 was used on the slides at a concentration of 1:20,000. The
primary antibody was detected using a biotin-labeled streptavidin
system. The chromagen was DAB with hematoxylin counterstain.
[0170] Cross-sectional views of skeletal muscle show distinct
outlining of muscle fibers with Acrp30 staining. A positive signal
is also seen in any blood vessels in the tissue. This is not
surprising since the animals were not perfused before tissues were
isolated and Acrp30 should thus be present in the plasma that would
be in these vessels. This staining appears to be specific given
that tissues stained with preimmune at the same concentration were
clean. Also it should be noted that tissues without much Acrp30,
such as liver, do not show much Acrp30 staining.
[0171] The substantial presence of Acrp30 in skeletal muscle
supports the inventor's belief that muscle is in fact a target
tissue of this molecule.
Example 12
Generation of Globular ACRP3 of by Enzymatic Cleavage
[0172] Incubate purified Acrp30 (obtained as described above or
through equivalent method) with acetylated Trypsin-Type V-S from
Bovine Pancreas (Sigma E.C.=3.4.21.4) at 400 u/mg protein at
25.degree. C. for 10 min.
[0173] Stop reaction by running the sample over a Poly-Prep Column
(Biorad 731-1550) at +4.degree. C. containing immobilized Trypsin
inhibitor.
[0174] Collect 1.0 mL fractions. Determine protein
concentration.
[0175] Pool the protein containing fractions and dialyze
extensively against PBS using dialysis tubing with M.W.
cutoff=10,000 da.
[0176] Concentrate on Amicon YM-10 Centricon Filter (Millipore,
M.W. cutoff=10,000 da). Sterile filter.
[0177] Determine final protein concentration using Markwell's
modified Lowry procedure (1981) or BCA protein assay (Pierce
Chemical Co, Rockford, Ill.) and BSA as standard.
[0178] Check purity and efficiency of cleavage by SDS-PAGE analysis
using a 4-20% gradient gel. The intact Acrp30 migrates as a single
band at approx. 37 kda due to co-transcribed vector sequences
attached to the histidine tag at the N-terminus of Acrp30. The
cleaved Acrp30 forms a band at approx. 18 kda (gAcrp30). Additional
degradation products, all smaller than 10 kda are also generated
from the N-terminal region. These are separated from the desired 18
kda band by dialysis with semipermeable membranes with a MW cutoff
of 10,000. The actual cleavage site using this method has been
identified as the one after amino acid 103.
REFERENCES
[0179] Dehouck et al. J Neurochem 54:1798-801, 1990 [0180] Shapiro,
and Scherer, Curr. Biol. 8:335-338, 1998 [0181] Uysal, et al.
Nature 389:610-614, 1997
Sequence CWU 1
1
711152DNAmus musculus 1gaattcggca cgaggg atg cta ctg ttg caa gct
ctc ctg ttc ctc tta atc 52Met Leu Leu Leu Gln Ala Leu Leu Phe Leu
Leu Ile1 5 10ctg ccc agt cat gcc gaa gat gac gtt act aca act gaa
gag cta gct 100Leu Pro Ser His Ala Glu Asp Asp Val Thr Thr Thr Glu
Glu Leu Ala 15 20 25cct gct ttg gtc cct cca ccc aag gga act tgt gca
ggt tgg atg gca 148Pro Ala Leu Val Pro Pro Pro Lys Gly Thr Cys Ala
Gly Trp Met Ala 30 35 40ggc atc cca gga cat tct ggc cac aat ggc aca
cca ggc cgt gat ggc 196Gly Ile Pro Gly His Ser Gly His Asn Gly Thr
Pro Gly Arg Asp Gly45 50 55 60aga gat ggc act cct gga gag aag gga
gag aaa gga gat tca ggt ctt 244Arg Asp Gly Thr Pro Gly Glu Lys Gly
Glu Lys Gly Asp Ser Gly Leu 65 70 75ctt ggt cct aag ggt gag aca gga
gat gtt gga atg aca gga gct gaa 292Leu Gly Pro Lys Gly Glu Thr Gly
Asp Val Gly Met Thr Gly Ala Glu 80 85 90ggg cct cgg ggc ttc ccc gga
acc cct ggc agg aaa gga gag cct gga 340Gly Pro Arg Gly Phe Pro Gly
Thr Pro Gly Arg Lys Gly Glu Pro Gly 95 100 105gaa gcc gct tat gtg
tat cgc tca ggc ttc agt gtg ggg ctg gag acc 388Glu Ala Ala Tyr Val
Tyr Arg Ser Gly Phe Ser Val Gly Leu Glu Thr 110 115 120cgc gtc act
gtt ccc aat gta ccc att cgc ttt act aag atc ttc tac 436Arg Val Thr
Val Pro Asn Val Pro Ile Arg Phe Thr Lys Ile Phe Tyr125 130 135
140aac caa cag aat cat tat gac aac agc act ggc aag ttc tac tgc aac
484Asn Gln Gln Asn His Tyr Asp Asn Ser Thr Gly Lys Phe Tyr Cys Asn
145 150 155att ccg gga ctc tac tac ttc tct tac cac atc acg gtg tac
atg aaa 532Ile Pro Gly Leu Tyr Tyr Phe Ser Tyr His Ile Thr Val Tyr
Met Lys 160 165 170gat gtg aag gtg agc ctc ttc aag aag gac aag gcc
gtt ctc ttc acc 580Asp Val Lys Val Ser Leu Phe Lys Lys Asp Lys Ala
Val Leu Phe Thr 175 180 185tac gac cag tat cag gaa aag aat gtg gac
cag gcc tct ggc tct gtg 628Tyr Asp Gln Tyr Gln Glu Lys Asn Val Asp
Gln Ala Ser Gly Ser Val 190 195 200ctc ctc cat ctg gag gtg gga gac
caa gtc tgg ctc cag gtg tat ggg 676Leu Leu His Leu Glu Val Gly Asp
Gln Val Trp Leu Gln Val Tyr Gly205 210 215 220gat ggg gac cac aat
gga ctc tat gca gat aac gtc aac gac tct aca 724Asp Gly Asp His Asn
Gly Leu Tyr Ala Asp Asn Val Asn Asp Ser Thr 225 230 235ttt act ggc
ttt ctt ctc ttc cat gat acc aac tga ctgcaactac 770Phe Thr Gly Phe
Leu Leu Phe His Asp Thr Asn 240 245tcatagccca tacaccagga gaatcatgga
acgtcgacac actttcagct tagtttgaga 830gattgatttt attgcttagt
ttgagagtcc tgagtattat ccacacgtgt actcacttgt 890tcattaaacg
actttataaa aaataatttg tgttcctagt ccagaaaaaa aggcactccc
950tggtctccac gactcttaca tggtagcaat aacagaatga aaatcacatt
tggtatgggg 1010gcttcacaat attcgcatga ctgtctggaa gtagaccatg
ctatttttct gctcactgta 1070cacaaatatt gttcacataa accctataat
gtaaatatga aatacagtga ttatcttctc 1130aaaaaaaact cgtgccgaat tc
11522247PRTmus musculus 2Met Leu Leu Leu Gln Ala Leu Leu Phe Leu
Leu Ile Leu Pro Ser His1 5 10 15Ala Glu Asp Asp Val Thr Thr Thr Glu
Glu Leu Ala Pro Ala Leu Val 20 25 30Pro Pro Pro Lys Gly Thr Cys Ala
Gly Trp Met Ala Gly Ile Pro Gly 35 40 45His Ser Gly His Asn Gly Thr
Pro Gly Arg Asp Gly Arg Asp Gly Thr 50 55 60Pro Gly Glu Lys Gly Glu
Lys Gly Asp Ser Gly Leu Leu Gly Pro Lys65 70 75 80Gly Glu Thr Gly
Asp Val Gly Met Thr Gly Ala Glu Gly Pro Arg Gly 85 90 95Phe Pro Gly
Thr Pro Gly Arg Lys Gly Glu Pro Gly Glu Ala Ala Tyr 100 105 110Val
Tyr Arg Ser Gly Phe Ser Val Gly Leu Glu Thr Arg Val Thr Val 115 120
125Pro Asn Val Pro Ile Arg Phe Thr Lys Ile Phe Tyr Asn Gln Gln Asn
130 135 140His Tyr Asp Asn Ser Thr Gly Lys Phe Tyr Cys Asn Ile Pro
Gly Leu145 150 155 160Tyr Tyr Phe Ser Tyr His Ile Thr Val Tyr Met
Lys Asp Val Lys Val 165 170 175Ser Leu Phe Lys Lys Asp Lys Ala Val
Leu Phe Thr Tyr Asp Gln Tyr 180 185 190Gln Glu Lys Asn Val Asp Gln
Ala Ser Gly Ser Val Leu Leu His Leu 195 200 205Glu Val Gly Asp Gln
Val Trp Leu Gln Val Tyr Gly Asp Gly Asp His 210 215 220Asn Gly Leu
Tyr Ala Asp Asn Val Asn Asp Ser Thr Phe Thr Gly Phe225 230 235
240Leu Leu Phe His Asp Thr Asn 24531276DNAmus musculus 3ctctaaagat
tgtcagtgga tctgacgaca ccaaaagggc tcagg atg cta ctg ttg 57Met Leu
Leu Leu1caa gct ctc ctg ttc ctc tta atc ctg ccc agt cat gcc gaa gat
gac 105Gln Ala Leu Leu Phe Leu Leu Ile Leu Pro Ser His Ala Glu Asp
Asp5 10 15 20gtt act aca act gaa gag cta gct cct gct ttg gtc cct
cca ccc aag 153Val Thr Thr Thr Glu Glu Leu Ala Pro Ala Leu Val Pro
Pro Pro Lys 25 30 35gga act tgt gca ggt tgg atg gca ggc atc cca gga
cat cct ggc cac 201Gly Thr Cys Ala Gly Trp Met Ala Gly Ile Pro Gly
His Pro Gly His 40 45 50aat ggc aca cca ggc cgt gat ggc aga gat ggc
act cct gga gag aag 249Asn Gly Thr Pro Gly Arg Asp Gly Arg Asp Gly
Thr Pro Gly Glu Lys 55 60 65gga gag aaa gga gat gca ggt ctt ctt ggt
cct aag ggt gag aca gga 297Gly Glu Lys Gly Asp Ala Gly Leu Leu Gly
Pro Lys Gly Glu Thr Gly 70 75 80gat gtt gga atg aca gga gct gaa ggg
cca cgg ggc ttc ccc gga acc 345Asp Val Gly Met Thr Gly Ala Glu Gly
Pro Arg Gly Phe Pro Gly Thr85 90 95 100cct ggc agg aaa gga gag cct
gga gaa gcc gct tat atg tat cgc tca 393Pro Gly Arg Lys Gly Glu Pro
Gly Glu Ala Ala Tyr Met Tyr Arg Ser 105 110 115gcg ttc agt gtg ggg
ctg gag acc cgc gtc act gtt ccc aat gta ccc 441Ala Phe Ser Val Gly
Leu Glu Thr Arg Val Thr Val Pro Asn Val Pro 120 125 130att cgc ttt
act aag atc ttc tac aac caa cag aat cat tat gac ggc 489Ile Arg Phe
Thr Lys Ile Phe Tyr Asn Gln Gln Asn His Tyr Asp Gly 135 140 145agc
act ggc aag ttc tac tgc aac att ccg gga ctc tac tac ttc tct 537Ser
Thr Gly Lys Phe Tyr Cys Asn Ile Pro Gly Leu Tyr Tyr Phe Ser 150 155
160tac cac atc acg gtg tac atg aaa gat gtg aag gtg agc ctc ttc aag
585Tyr His Ile Thr Val Tyr Met Lys Asp Val Lys Val Ser Leu Phe
Lys165 170 175 180aag gac aag gcc gtt ctc ttc acc tac gac cag tat
cag gaa aag aat 633Lys Asp Lys Ala Val Leu Phe Thr Tyr Asp Gln Tyr
Gln Glu Lys Asn 185 190 195gtg gac cag gcc tct ggc tct gtg ctc ctc
cat ctg gag gtg gga gac 681Val Asp Gln Ala Ser Gly Ser Val Leu Leu
His Leu Glu Val Gly Asp 200 205 210caa gtc tgg ctc cag gtg tat ggg
gat ggg gac cac aat gga ctc tat 729Gln Val Trp Leu Gln Val Tyr Gly
Asp Gly Asp His Asn Gly Leu Tyr 215 220 225gca gat aac gtc aac gac
tct aca ttt act ggc ttt ctt ctc tac cat 777Ala Asp Asn Val Asn Asp
Ser Thr Phe Thr Gly Phe Leu Leu Tyr His 230 235 240gat acc aac tga
ctgcaactac ccatagccca tacaccagga gaatcatgga 829Asp Thr
Asn245acagtcgaca cactttcagc ttagtttgag agattgattt tattgcttag
tttgagagtc 889ctgagtatta tccacacgtg tactcacttg ttcattaaac
gactttataa aaaataattt 949gtgttcctag tccagaaaaa aaggcactcc
ctggtctcca cgactcttac atggtagcaa 1009taacagaatg aaaatcacat
ttggtatggg ggcttcacaa tattcgcatg actgtctgga 1069agtagaccat
gctatttttc tgctcactgt acacaaatat tgttcacata aaccctataa
1129tgtaaatatg aaatacagtg attactcttc tcacaggctg agtgtatgaa
tgtctaaaga 1189cccataagta ttaaagtggt agggataaat tggaaaaaaa
aaaaaaaaaa aagaaaaact 1249ttagagcaca ctggcggccg ttactag
12764247PRTmus musculus 4Met Leu Leu Leu Gln Ala Leu Leu Phe Leu
Leu Ile Leu Pro Ser His1 5 10 15Ala Glu Asp Asp Val Thr Thr Thr Glu
Glu Leu Ala Pro Ala Leu Val 20 25 30Pro Pro Pro Lys Gly Thr Cys Ala
Gly Trp Met Ala Gly Ile Pro Gly 35 40 45His Pro Gly His Asn Gly Thr
Pro Gly Arg Asp Gly Arg Asp Gly Thr 50 55 60Pro Gly Glu Lys Gly Glu
Lys Gly Asp Ala Gly Leu Leu Gly Pro Lys65 70 75 80Gly Glu Thr Gly
Asp Val Gly Met Thr Gly Ala Glu Gly Pro Arg Gly 85 90 95Phe Pro Gly
Thr Pro Gly Arg Lys Gly Glu Pro Gly Glu Ala Ala Tyr 100 105 110Met
Tyr Arg Ser Ala Phe Ser Val Gly Leu Glu Thr Arg Val Thr Val 115 120
125Pro Asn Val Pro Ile Arg Phe Thr Lys Ile Phe Tyr Asn Gln Gln Asn
130 135 140His Tyr Asp Gly Ser Thr Gly Lys Phe Tyr Cys Asn Ile Pro
Gly Leu145 150 155 160Tyr Tyr Phe Ser Tyr His Ile Thr Val Tyr Met
Lys Asp Val Lys Val 165 170 175Ser Leu Phe Lys Lys Asp Lys Ala Val
Leu Phe Thr Tyr Asp Gln Tyr 180 185 190Gln Glu Lys Asn Val Asp Gln
Ala Ser Gly Ser Val Leu Leu His Leu 195 200 205Glu Val Gly Asp Gln
Val Trp Leu Gln Val Tyr Gly Asp Gly Asp His 210 215 220Asn Gly Leu
Tyr Ala Asp Asn Val Asn Asp Ser Thr Phe Thr Gly Phe225 230 235
240Leu Leu Tyr His Asp Thr Asn 24554517DNAHomo sapiens 5ctgattccat
accagagggg ctcagg atg ctg ttg ctg gga gct gtt cta ctg 53Met Leu Leu
Leu Gly Ala Val Leu Leu1 5cta tta gct ctg ccc ggg cat gac cag gaa
acc acg act caa ggg ccc 101Leu Leu Ala Leu Pro Gly His Asp Gln Glu
Thr Thr Thr Gln Gly Pro10 15 20 25gga gtc ctg ctt ccc ctg ccc aag
ggg gcc tgc aca ggt tgg atg gcg 149Gly Val Leu Leu Pro Leu Pro Lys
Gly Ala Cys Thr Gly Trp Met Ala 30 35 40ggc atc cca ggg cat ccg ggc
cat aat ggg gcc cca ggc cgt gat ggc 197Gly Ile Pro Gly His Pro Gly
His Asn Gly Ala Pro Gly Arg Asp Gly 45 50 55aga gat ggc acc cct ggt
gag aag ggt gag aaa gga gat cca ggt ctt 245Arg Asp Gly Thr Pro Gly
Glu Lys Gly Glu Lys Gly Asp Pro Gly Leu 60 65 70att ggt cct aag gga
gac atc ggt gaa acc gga gta ccc ggg gct gaa 293Ile Gly Pro Lys Gly
Asp Ile Gly Glu Thr Gly Val Pro Gly Ala Glu 75 80 85ggt ccc cga ggc
ttt ccg gga atc caa ggc agg aaa gga gaa cct gga 341Gly Pro Arg Gly
Phe Pro Gly Ile Gln Gly Arg Lys Gly Glu Pro Gly90 95 100 105gaa ggt
gcc tat gta tac cgc tca gca ttc agt gtg gga ttg gag act 389Glu Gly
Ala Tyr Val Tyr Arg Ser Ala Phe Ser Val Gly Leu Glu Thr 110 115
120tac gtt act atc ccc aac atg ccc att cgc ttt acc aag atc ttc tac
437Tyr Val Thr Ile Pro Asn Met Pro Ile Arg Phe Thr Lys Ile Phe Tyr
125 130 135aat cag caa aac cac tat gat ggc tcc act ggt aaa ttc cac
tgc aac 485Asn Gln Gln Asn His Tyr Asp Gly Ser Thr Gly Lys Phe His
Cys Asn 140 145 150att cct ggg ctg tac tac ttt gcc tac cac atc aca
gtc tat atg aag 533Ile Pro Gly Leu Tyr Tyr Phe Ala Tyr His Ile Thr
Val Tyr Met Lys 155 160 165gat gtg aag gtc agc ctc ttc aag aag gac
aag gct atg ctc ttc acc 581Asp Val Lys Val Ser Leu Phe Lys Lys Asp
Lys Ala Met Leu Phe Thr170 175 180 185tat gat cag tac cag gaa aat
aat gtg gac cag gcc tcc ggc tct gtg 629Tyr Asp Gln Tyr Gln Glu Asn
Asn Val Asp Gln Ala Ser Gly Ser Val 190 195 200ctc ctg cat ctg gag
gtg ggc gac caa gtc tgg ctc cag gtg tat ggg 677Leu Leu His Leu Glu
Val Gly Asp Gln Val Trp Leu Gln Val Tyr Gly 205 210 215gaa gga gag
cgt aat gga ctc tat gct gat aat gac aat gac tcc acc 725Glu Gly Glu
Arg Asn Gly Leu Tyr Ala Asp Asn Asp Asn Asp Ser Thr 220 225 230ttc
aca ggc ttt ctt ctc tac cat gac acc aac tga tcaccactaa 771Phe Thr
Gly Phe Leu Leu Tyr His Asp Thr Asn 235 240ctcagagcct cctccaggcc
aaacagcccc aaagtcaatt aaaggctttc agtacggtta 831ggaagttgat
tattatttag ttggaggcct ttagatatta ttcattcatt tactcattca
891tttattcatt cattcatcaa gtaactttaa aaaaatcata tgctatgttc
ccagtcctgg 951ggagcttcac aaacatgacc agataactga ctagaaagaa
gtagttgaca gtgctatttt 1011gtgcccactg tctctcctga tgctcatatc
aatcctataa ggcacaggga acaagcattc 1071tcctgttttt acagattgta
tcctgaggct gagagagtta agtgaatgtc taaggtcaca 1131cagtattaag
tgacagtgct agaaatcaaa cccagagctg tggactttgt tcactagact
1191gtgccctttt atagaggtac atgttctctt tggagtgttg gtaggtgtct
gtttcccacc 1251tcacctgaga gccattgaat ttgccttcct catgaattaa
aacctccccc aagcagagct 1311tcctcagaga aagtggttct atgatgaagt
cctgtcttgg aaggactact actcaatggc 1371ccctgcacta ctctacttcc
tcttacctat gtcccttctc atgcctttcc ctccaacggg 1431gaaagccaac
tccatctcta agtgctgaac tcatccctgt tcctcaaggc cacctggcca
1491ggagcttctc tgatgtgata tccacttttt tttttttttg agatggagtc
tcactctgtc 1551acccaggctg gagtacagtg acacgacctc ggctcactgc
agcctccttc tcctgggtcc 1611aagcaattat tgtgcctcag cctcccgagt
agctgagact tcaggtgcat tccaccacac 1671atggctaatt tttgtatttt
tagtagaaat ggggtttcgt catgttggcc aggctggtct 1731cgaactcctg
gcctaggtga tccacccgcc tcgacctccc aaagtgctgg gattacaggc
1791atgagccacc atgcccagtc gatatctcac tttttatttt gccatggatg
agagtcctgg 1851gtgtgaggaa cacctcccac caggctagag gcaactgccc
aggaaggact gtgcttccgt 1911cacctctaaa tcccttgcag atccttgata
aatgcctcat gaagaccaat ctcttgaatc 1971ccatatctac ccagaattaa
ctccattcca gtctctgcat gtaatcagtt ttatccacag 2031aaacattttc
attttaggaa atccctggtt taagtatcaa tccttgttca gctggacaat
2091atgaatcttt tccactgaag ttagggatga ctgtgatttt cagaacacgt
ccagaatttt 2151tcatcaagaa ggtagcttga gcctgaaatg caaaacccat
ggaggaattc tgaagccatt 2211gtctccttga gtaccaacag ggtcagggaa
gactgggcct cctgaattta ttattgttct 2271ttaagaatta caggttgagg
tagttgatgg tggtaaacat tctctcagga gacaataact 2331ccagtgatgt
ttttcaaaga ttttagcaaa aacagagtaa atagcattct ctatcaatat
2391ataaatttaa aaaactatct ttttgcttac agttttaaat tctgaacaat
ttctcttata 2451tgtgtattgc taatcattaa ggtattattt tttccacata
taaagctttg tctttttgtt 2511gttgttgttg tttttaagat ggagtttccc
tctgttgcca ggctagagtg cagtggcatg 2571atctcggctt actgcaacct
ttgcctccca ggtttaagcg attcttctgc ctcagcctcc 2631cgagtagctg
ggaccacagg tgcctaccac catgccaggc taatttttgt atttttagta
2691aagacagggt ttcaccatat tggccaggct ggtctcgaac tcctgacctt
gtgatctgcc 2751cgcctccatt gtgttgttat ttgtgagaaa gatagatatg
aggtttagag agggatgaag 2811aggtgagagt aagccttgtg ttagtcagaa
ctctgtgttg tgaatgtcat tcacaacaga 2871aaacccaaaa tattatgcaa
actactgtaa gcaagaaaaa taaaggaaaa atggaaacat 2931ttattccttt
gcataataga aattaccaga gttgttctgt ctttagataa ggtttgaacc
2991aaagctcaaa acaatcaaga cccttttctg tatgtccttc tgttctgcct
tccgcagtgt 3051aggctttacc ctcaggtgct acacagtata gttctagggt
ttccctcccg atatcaaaaa 3111gactgtggcc tgcccagctc tcgtatcccc
aagccacacc atctggctaa atggacatca 3171tgttttctgg tgatgcccaa
agaggagaga ggaagctctc tttcccagat gccccagcaa 3231gtgtaacctt
gcatctcatt gctctggctg agttgtgtgc ctgtttctga ccaatcactg
3291agtcaggagg atgaaatatt catattgact taattgcagc ttaagttagg
ggtatgtaga 3351ggtattttcc ctaaagcaaa attgggacac tgttatcaga
aataggagag tggatgatag 3411atgcaaaata atacctgtcc acaacaaact
cttaatgctg tgtttgagct ttcatgagtt 3471tcccagagag acatagctgg
aaaattccta ttgattttct ctaaaatttc aacaagtagc 3531taaagtctgg
ctatgctcac agtctcacat ctggtggggg tgggctcctt acagaacacg
3591ctttcacagt taccctaaac tctctggggc agggttattc ctttgtggaa
ccagaggcac 3651agagacagtc aactgaggcc caacagaggc ctgagagaaa
ctgaggtcaa gatttcagga 3711ttaatggtcc tgtgatgctt tgaagtacaa
ttgtggattt gtccaattct ctttagttct 3771gtcagctttt gcttcatata
ttttagcgct ctattattag atatatacat gtttagtatt 3831atgtcttatt
ggtgcattta ctctcttatc attatgtaat gtccttcttt atctgtgata
3891attttctgtg ttctgaagtc tactttgtct aaaaataaca tacgcactca
acttcctttt 3951ctttcttcct tcctttcttt cttccttcct ttctttctct
ctctctcttt ccttccttcc 4011ttcctccttt tctctctctc tctctctctc
tctcttttct tgacagactc tcgttctgtg 4071gccctggctg gagttcagtg
gtgtgatctt ggctcactgc tacctctacc atgagcaatt 4131ctcctgcctc
agcctcccaa gtagctggaa ctacaggctc atgccactgc gcccagctaa
4191tttttgtatt tttcgtagag acggggtttc accacattcg tcaggttggt
ttcaaactcc 4251tgactttgtg atccacccgc ctcggcctcc caaagtgctg
ggattacagg catgagccat 4311cacacctggt caactttctt ttgattagtg
tttttgtggt atatcttttt ccatcatgtt 4371actttaaata tatctatatt
attgtattta aaatgtgttt cttacagact gcatgtagtt 4431gggtataatt
tttatccagt ctaaaaatat ctgtctttta
attggtgttt agacaattta 4491tatttaataa aatggtggaa tttaaa
45176244PRTHomo sapiens 6Met Leu Leu Leu Gly Ala Val Leu Leu Leu
Leu Ala Leu Pro Gly His1 5 10 15Asp Gln Glu Thr Thr Thr Gln Gly Pro
Gly Val Leu Leu Pro Leu Pro 20 25 30Lys Gly Ala Cys Thr Gly Trp Met
Ala Gly Ile Pro Gly His Pro Gly 35 40 45His Asn Gly Ala Pro Gly Arg
Asp Gly Arg Asp Gly Thr Pro Gly Glu 50 55 60Lys Gly Glu Lys Gly Asp
Pro Gly Leu Ile Gly Pro Lys Gly Asp Ile65 70 75 80Gly Glu Thr Gly
Val Pro Gly Ala Glu Gly Pro Arg Gly Phe Pro Gly 85 90 95Ile Gln Gly
Arg Lys Gly Glu Pro Gly Glu Gly Ala Tyr Val Tyr Arg 100 105 110Ser
Ala Phe Ser Val Gly Leu Glu Thr Tyr Val Thr Ile Pro Asn Met 115 120
125Pro Ile Arg Phe Thr Lys Ile Phe Tyr Asn Gln Gln Asn His Tyr Asp
130 135 140Gly Ser Thr Gly Lys Phe His Cys Asn Ile Pro Gly Leu Tyr
Tyr Phe145 150 155 160Ala Tyr His Ile Thr Val Tyr Met Lys Asp Val
Lys Val Ser Leu Phe 165 170 175Lys Lys Asp Lys Ala Met Leu Phe Thr
Tyr Asp Gln Tyr Gln Glu Asn 180 185 190Asn Val Asp Gln Ala Ser Gly
Ser Val Leu Leu His Leu Glu Val Gly 195 200 205Asp Gln Val Trp Leu
Gln Val Tyr Gly Glu Gly Glu Arg Asn Gly Leu 210 215 220Tyr Ala Asp
Asn Asp Asn Asp Ser Thr Phe Thr Gly Phe Leu Leu Tyr225 230 235
240His Asp Thr Asn720966DNAHomo sapiensmisc_feature1..48115'
regulatory region 7gctgatctgc tgcctcagcc ttcccaaagt gctgtaattt
attaggcata agccactgtg 60cctgcctagt gttgtacatt ctgtgggttt tgacaattgt
atgcatctac atgtatgtac 120catttatagt attcctgttt ttaattttag
ccattctagt aggcatgtag tgatatctca 180tggtgatttt aatttgcgtt
tccgtaatgg ttaataatgc tgaacatctt tgcatgtgct 240tgtttgtcat
ttgtgtttcc tacttggtga aataattgtt catgtccttt gtccattttc
300taattgaatt tttttttacc atttagtttt gagatttctt tatacaatct
agatccaaat 360ctcttgtctc aaatatggtt tgcaaataca ttcctctaat
tcatatattg ccttttcctc 420ctcttaacag gatgtttcac agagcaaaag
ttttagtttt gttgaaatct cacttttcat 480ttttttcttt agtggattgt
gcttttgttg tcatatgtaa gaactcttca ctggccctag 540atccttgtat
tggtttccta agattgccat agcaaatcac catgaactta gtgacaaaaa
600gacagaaatt tattttcact tcctactgtg ggcagactag acgttaatta
ttttcatgta 660tgctcattcc tatgacatct ttctgatata ataattatag
ttattcttaa gcttcaccct 720tttttctatt agctttgtta ccttgggtgt
cactttttct tttttgacat tgtgacctat 780gccagatcat gtctgttagt
acttagccct ccattcacct ctccataatc ccttttgtat 840tcctggagct
tgatgcctga aatgacacat cctacattcc tttgccagat gggtaccagt
900tagcttgtgc acatgggaga caaccgtgaa aagactgaag tggggaagaa
gggaggagct 960gttgtgtttc agtgagcgcc cttggcagtg gcggtgacag
tggctcctgt tcagtggcaa 1020tggtggagca gctagcaaga catgcagtaa
gcgcaggctc ataggctatg gtccaggagc 1080agtcaccgat tcctggtctt
taggcaatat catctccctt tgcttctcca gcctttctaa 1140aattattgta
ccttgactag tacaattttt tagtattggg ggtagtccaa ggacacaggc
1200tttaaaaagt atgaattcag ggttgcctac ctgcattgac tgcgcttgaa
tcatgatggc 1260cttctggtcg gtggcaggag gtgacagtcc aaatcatgca
gtagcaaacc agatacttaa 1320attatcatct gagatacttc agaagtacag
ccgtagccat accttcagaa gagataaaga 1380aatgttctcc tggccaggcg
cggtggctca cgcctgtcat tccagcactt tgggaggccg 1440agggggtgga
tcacctgagg tcgggagttc gagaccagcc tgaccaacat ggggaaaccc
1500tgtctctact aaaaatacaa aattagcggg gcgtggtggc acatgcccat
aatcccagct 1560actcgggagg ctaaggcagg ataatcgctt gaacctgaga
ggcagaggtt gcggtgaact 1620gagatcatgc catagtactc cagcctgggc
aacaagagtg aaactccatc tcaaaaaaaa 1680aaaaaagaaa aaaagataaa
gaaatgttct cctttcttgc catttctagg ggtttgggga 1740tggcgtacat
tgctgcaggg cgtgctcact ctaccatctt gctccaatct ttatttttca
1800aaatacagtg cttatgcttg gttacttcag ttaagattat ttttaaaaat
cataattaag 1860caaaaatata tggccatgct taaacatatt taagataaat
taagtgattt ggcctgtttc 1920agtatcccaa ctcacatgct aacaggggct
tgacctgtag ctacggtacc ctggaggaaa 1980tgatcgcatt tatttggtta
tttcggtcta agtagtaata gttctgtcct gggaaaaaga 2040ctagcctcaa
ggcatttctg attgaatgtt tttcaattac agtctttaaa ccagtatgcc
2100acagaactgg ctctttccac atgacggcct ttgtggtggg tggcagattg
ccctgaggcc 2160tcgcaaaatg ctaggctttc acaatgtcac tgactgacag
ccaggcccag cacagtcttg 2220gtgtgattgt ggggctaaag ttattccacc
ttgtgcaata gctacagcct tctctaacca 2280gctgcattct tataaagtta
gaagaaaata cttttttttt tttgagatgg attctcgctc 2340tgttgcccag
gctggagtgc aatggtgcga tctcggctcg ctgcaacctc cgcctcctgg
2400gttcaaacga ttctcctccc tcagaccccc gagtagctgg gattgcaggt
gcctgccacc 2460acgcccggct aacttttttg tatttttagt ggagacgggg
tttcaccatc ttcgtcaggc 2520tggtctcaga ctcctgacct caagtgatct
gcccgcctca gcctcccaaa atgctgggat 2580tacaggcatg agctactgtg
cccggccaaa gaaaatactt tttatgccag ccctgaaact 2640accctgaagc
acatacatca accttgaggc ctcacactcc atcaagaggg gtgaagggca
2700tgaggaatta gaaagcatag ggatttttag ttagacagat ctggttcaaa
tcctagactt 2760gtgccttgaa caaattattt accctcattg aactctagat
tcattatttg taaaatgaaa 2820gacaataata gttatctcca aaggaaagtt
gaatatgatc attcatttat tcattaattc 2880aacatttatt attgcctact
ttgtgccagg ttctattcta ggaactaagg gatacaactt 2940tgaataggca
aaatctctgc tctcctgaag tttacttttt tttttttttt ttgagacaga
3000gtttcactct tgtcacccag gctggagcgc aatggtgctc ttggctcact
gcaacctcca 3060cctcctgggt tcaagtgatt ctcttgtctc agcctcccaa
gtagctggga ctacaggtat 3120gtgccaccac gcccggctat ttctgcattt
ttagtagaga tggggtttca ccatgttggc 3180cagactggtc tcaaactcct
gatctcaggt gatatgcctg tcttggcctt ccaaagtact 3240gggattacag
gcctgagcca ctgcacctga cctgaagttt atgttctatt aaatagcaac
3300agacagtaac ataaaccaaa aataaatagg aaaacaccat aacaaaaatc
aaacagtgat 3360ataattgaga gttgcttcta tttctttttg ttgtcttctt
ggttcaatca gcctgctaaa 3420ctatatggaa cctcattttc atgggccact
tatttaagcc gggggacctt ggaaagtctc 3480tcatgtctct catctcaacg
gcctaatgtg acttctcttg aaatatttgg acattagcag 3540gaagctgagg
ctttacatca gatctttact ttaatggtgg acttgacttt actggtagat
3600ttttaggctc tgtgtggact gtggagatga tatctggggg gcaggcagac
acttgccctg 3660cctctgtctg agaaaattct gttttggatg tcttgttgaa
gttggtgctg gcatcctaag 3720cccttgctgg ggtcgtaatt taattcatca
gaatgtgtgg cttgcaagaa ccggctcaga 3780tcctgcsctt caaaaacaaa
acatgagcgt gccaagaaag tccaaggtgt tgaatgttgc 3840cacttcaagc
ctaaactttc taggaacacc taagtgggtg gcagcttcca gttctccagg
3900ctgcttctag gccagagctg ggttccacaa gagacagaat aggcatatat
atgcttaagg 3960aactggaaaa acaggctctc tctctctcac aaacacacac
acacacatac caaggtagct 4020gtcaaaatgt tatccgaaat tttggaacca
aaaaatcttg aaagatggta ttccaatatc 4080acattttatg taagttttct
attatattag attcaaatta cgattcgagg ccacaagctt 4140taagaattca
gggccttttt aacttgccaa gccccacacc actccaggaa cttccccaca
4200ccccagttct cagaattcat gtgcaaggtc tttcctaaat ccagggtcca
ggtcagagag 4260tggaggatgt gctctatttc ttacctgatt gcagacccct
ctgacagtgc tcccttctga 4320agcactcact gtctgaacgt acacagtctc
agacttaatc atgcacagtg agcaagactg 4380tggtgtgata attggcgtcc
ctgacttatt agggcaaatc tatgggaggg ggagacctcc 4440tggaccactg
agcaattaat tcatttacat taggaagttt ctccgtcaga tgcaggaaaa
4500aaatcttgtt ttcctgctgt ggttttgact tttgccccat cttctgttgc
tgttgtagga 4560ggcaaaataa gggtcaaggc ctggaaacac aagtgctttg
actgaagctc cacttggctt 4620ccgaagccca agctgggttg taccaggttc
cctagggtgc aggctgtggg caactgccag 4680ggacatgtgc ctgcccaccg
gcctctggcc ctcactgagt tggccaatgg gaaatgacaa 4740ttgtgaggtg
gggactgcct gcccccgtga gtaccaggct gttgaggctg ggccatctcc
4800tcctcacttc cattctgact gcagtctgtg gttctgattc cataccagag
ggtaagagca 4860attctgtgaa gttccaggct gggtggggga tgcatgcata
gcctctggct gggatcaccc 4920aggctctccc gtccgtagta gtgtgggagt
ggatacaggt ggatactctg gtcagagcag 4980cactggtgga ggcagatatg
cactgggctt cttcctccgt tctcccacag ccccaagaga 5040gaaagggtta
tttcagacat tccttctaag atgcatggaa ccattctgaa ttttacccag
5100ttcgctctgt agcaggatac ctattgagaa aaagttaggg tcagtaaggt
ggaagggtct 5160gtccacagat gaagtccaat tcgattaagg gggataaggg
aatacattgt ctcttagctt 5220gaccaggtag ggcaaaggaa gaagcatata
tgaaggcagc ttcagaaaag tcaagctgag 5280cactgacttc agactggaat
taggaatcca gctctgccac tttattctac tcagcaaata 5340tttactgagc
aaattctatg ggctagacag tggattgggt tcacaagata caatgagtgt
5400gacatggttg ttgtctatgg atttggggat atatgtaggt atagggatat
cttacaaggt 5460aatcaagagg ttctaatgag gccagccatg gtggctcaca
cctgtaatcc cagcaatttg 5520ggagaccgag gcgggtggat cacctgaggt
caggagttcc agactagcct gaccaacatg 5580gtgaaacccc gcctctacca
aaaatacaaa aattagttgg gcgtgatggc aggtgcctgt 5640aatcccagct
tctcgggagg ctgaggcagg agaattgtct gaacctggga ggcagaggtt
5700gcagtgagcc gagattgttg ccactgcatt ccagcctggg tgacagagcg
agactttgtg 5760tcaaaaaaaa aaaaaaaaag aaagaaaaga aaaagaggct
ctaatgagat aaaatgagaa 5820aagcctggca tgtagtggca acttatgaaa
aattgtaatt aaaaaaaaac attttctgac 5880agaagaaact ggatctacct
ggtttttctg aagcctaatc ctgctcgccc cagtgagtgc 5940tgtttctgag
gcatcctggt tgttttgagc tgtggatgct gaaggttaga gtgggaggga
6000ttttagaggt taggtctgcc cctcttgtgt tagaggacat ggatccctgg
tctggagagg 6060ttctggtttt tggatcaagc ctcacaaggg gtggcaccaa
ctcactccta ggaactccgc 6120tagaaggaag gccagctctg cctaattcgg
ttggggagat gggggtccct ttatgctagc 6180agaatatgtc cgaaggagca
tgatggtgtc agctttgttc atgaaggcca gtggtacaca 6240gggagcccgg
cagcttcctc agcagtccct gctgccactc ttccttaagt cttgaggagt
6300ctttttttgg cacaatctca gctcactgca acctccgcct cccaggttca
agcgattctc 6360ctgcctcagt ctcccaagta gctgagacta caggcatgcg
ccaccacgcc cagctaattt 6420ttatattttt agtagagatg gggttcacca
tattggccag gatggtctcg atctcttgac 6480ctcatattcc acctgcctcg
gcctcccaaa gtgctggtat tacaggtgtg agccactgcg 6540cctggccgag
gagtcttaag ctgagatcac agcattgcac tccagcctgg gcaaaaagag
6600caaaactcca tctcaaaaaa aaaaaaaaaa tagacacaag actggctcct
tgtctttttt 6660ggggacaggg tctcactcta tcacccaggc tggagtgcag
tggtgcaatc acagctcact 6720gcagcctcga tttcccaggc tcaagtgacc
ctcccatctt agcctcctga gtagctggga 6780ctacaggtgt gtgcaaccat
gcctggctaa tttttaaaaa ttttttgtag agatgaggtc 6840tcactatatt
ggctgggggg cctcaaactc ctgggctcag cagtcctccc acctcagcct
6900cccaaaaggc tgggattata tgcttgctct ttttaaggtg gctgtaggga
caaactttcc 6960acctactcct tgtcaagcca gtggaccggt ggtcccagac
atacggctaa agtcaagagg 7020tgatgtcttt tggagagata ctttcaatca
ggaatttcaa tcagaaattc aatcatgtgg 7080agagagactt atcctaaaaa
tgtggtggtg cgtgggatgc tctgttttat tagttccttg 7140acagtatgta
tgtgtgtgag tgtgtgtgtg tgcgcgcgca cactcatttg gatgggtgtg
7200tatgtgtgtg ggggggtggt gcgtacgtat gtggatgtgt ggatgtggtg
tgtgggtgtg 7260cgcgtgcata ggtggaggtg tgtgtatggg tgcgggtatg
tgtgtgtgtt gggcatggag 7320atattgacag ctctcccagg gctgagtgaa
ggctttcggg caaagctcct gggagctagg 7380caaagctgag ttgattcctg
gttatgccat ttattattgg gttgcaccgt gtgaaactgc 7440caatattcta
cactttgact tttatttatt tttattttta ttttttttga gacagagttt
7500cacacttgtc acctaggctg gagtgcagtg gcgcgatctc agctcactgc
aacctctgcc 7560tcatggattc aagtgattct cctgcctcag cctcccaagt
agctggaatt acaggtgccc 7620gctaccacgc ctgactaatt tttgtatttt
tggtagagac gggatttcac catgttgtcc 7680aggctggtct gaaactcctg
acatcaggta atccacccac ctcagcctcc caaagtgctg 7740ggattacagg
catgagccac tgcgcccggc ccattttgac ttttaaaaat gggagtttga
7800tataattcaa tccagtggtt gaattagcta gcatcgttcc ctctccaagt
ctcaggttct 7860cctacacgtt agagtcaaaa gcagggctat gggaagatta
agtaaaataa attttgaaaa 7920tgccttatga aaattacact ccaaagaact
cgcgccagtg tcagtgttct catgttcctc 7980atctcacatg atcacatttc
gcggattagg aagctgagtc tgagaagctc cgtgtagtgc 8040tttttcggag
gcaccgtgat gtgatggaag gctcactcgt taggaagtca gaacagagtc
8100tctgagggat catttcctta atctgtcagt ttcctcatct ctgaagttgg
gctcatttcc 8160ttccttcatg gagttattgt aaagatgaag ataaataacg
tgtaaaatct agcatgggaa 8220ctggcttcta taaggttcta ataagtgcat
tcctactcct tcccctcagc cttcccattt 8280gtaaaagcaa ggcaggggtg
aggtgatttc tggggctcct tttggctctg acatttgagg 8340attttgtatc
cttttttttt tcagagtctt gctctgtcac ccaggttgga gtgcagctca
8400atgcaaattc cgcctcccag gctcaagcaa ttcttatgtc tcagcctcct
gagtacctgg 8460gattacaggc aggcaccacc acccccagct aattttttgt
attttcagta gagacggggt 8520tttgccatat tggccaggct ggtcttgaac
tcctgacttc atgtgaccca cccatctcag 8580cctcccaaag tgctgagatg
acaggtgtga gctaccgtgc ctggccaatt ttgtgtgctt 8640taatgccctt
ttctgctgga agagttggca ccaggtttgg tgatctcttt cccccacacg
8700gctctgcctc ctgccagtcc cagaggggac cctgtccttg catttcacag
gattctgctg 8760ttgcaactga aattccagta ggtcaaagtg aaatttctca
tacactttaa catgaagata 8820aatgatcaca gtatggccct ttaggatcct
gagaacatca cggtcatccc ctggtataat 8880tttaaaagca gatgaatcca
tgcctgtgcg aggtttgcca ggaaagccag tgctgggatt 8940acagtggaag
tctttttatg ctactttttt cttgtatccc tcaccccatg gggtggcata
9000ttgaaaggca ggatgtgtga ccacgatact tttctcctcc tggactatgt
ctaagagtct 9060gttattgggt tctgaagatc agagtttaat ttccgactcc
tctctgtgta gctctgggat 9120cttggaaagc cacttaacct ttctgaagtc
ccctttcctc atctctaaaa tgcatacact 9180catcactaac atttactgag
cactgacatg tgccagacac cattctaagc attttacaca 9240gactacacca
tttgatcttc caacaaacag aacactgaaa cgcattacag gtcagaacaa
9300atgatttgtg cctaagcacc aagaccgtag agcccgtgct ccctattcta
ccctatcctg 9360tctctcaaaa tgattgtgag aatcgaatga gacactaggt
gagaaaaggg ttttataaat 9420agcattttaa aaatttttta aagtccacaa
aatttttaat tttaatacag ataaaataga 9480tccctttgtt ttataaaaag
taacaaaatt tgttatacaa caactatgtt atttattaat 9540tttgcctttt
tgtatgctgc caggaaagaa acattaagaa atcttaaatt gattatggtg
9600aatcagaagg tctgcctgga ctttttattg ctctaactgt acagctgatc
atactacctc 9660attttttttt atgacacttc aagggtgcgc ttagcttcat
cactccttcg ttgccaaaag 9720ctttgtgacc aaaaacaatt aagcagattc
ctgagtcact aaatgacaca taaccagagt 9780tgagacttag gaacttttag
tgccatgcta agcccacagg gacacaacaa atagcatttt 9840acaaaggcaa
agaattgtga cacttgagat ttagcttgtt gatccttgta aaagttttct
9900ttttaggcat aattgagttt tagatcatag tactcactat tacttagtaa
taattttttt 9960ctgatagaaa tacagtgtaa caggccgggc gcagtggctc
atgcctgtaa tcccagcact 10020ttgggaggcc gaggcgggcg gatcacttga
ggtcaggagt ttgagaccag cccggccaac 10080atggtgaaat cccatctcta
ctaaaaatac aaaaaattag ccaggtgtgg tcgtggattc 10140ctgtgatccc
agctacttgg gagggtgagg caggagcatc agttgaaccc aggaggcgga
10200ggttgcagtg agccaagatg gtgccattgc actccagcct gggccacaaa
gcgagactcc 10260acttcagaaa caaaaaaaaa aagagagaga gagaaaagaa
ggaaggaagg aaggaaggaa 10320ggaaagaagg aaggaaggaa ggaaagaagg
aaggaaggaa ggaaggaaag aaggaaggaa 10380ggaaagaagg aaggaaggaa
agaaggaagg aaggaaggaa ggaagggtaa caagcaaagt 10440gtaacaatgg
caatatctaa aaaaataggt atttttatat gtttgtcgtt ttatatatat
10500gacccccact ttagagatga ggaaactgag agattaagga aacgatccct
gagagactct 10560gttctgactt ccaaatcggt gagctttcca tcgcatcacg
gtgcctccga aagcatgaca 10620cggagcttct cagacttagc ttcctaatcc
gctaaacggg attatgtgag atgaggaaca 10680tgagaacgct gacatgggtg
agggttcctt ggagtatcat tttcatgtgg cattttcaaa 10740acttatttta
cctaatcttc ccaaagccct gcttttgact ctaatgtgtc tcctgagact
10800tggagagcgc aagatgctag cgacagagca agactccatc tccagataaa
taaataagta 10860aaataaaaaa gaacacaaat aattttgaaa atttttttga
aaattaggca cgtttgcact 10920gaccttcaat tgttattaat tgctggtttc
ccacccagaa ttaagttgga atgcaacttt 10980cttttacaat cagagtccgt
tcttggtctt ggaaacttct gaggctcctg tgctaatccc 11040actcttgtat
ttttggcacc tctaccccgt gccactgtca tggaacccag gctgatcgca
11100cctattagtg gagaaatmtg tccataatac tgaagtttgg ggacaaacag
tgttccctta 11160gggtaggaga aagagatctt tatttttaac aaagggggag
gagccagaaa actccagaga 11220cccctgagtt tgccctctct ccaaggtttg
gggtaagccc cccgtcaccc tttatctctg 11280gggctttcac atattctgga
ttctctcctc ctgtttccca gcagaaaagg atggagcctc 11340acagattctt
cccatttctg gagaaaaaca tgcatggagc tcaaagttct tctcaggagt
11400tttattgcca aagccataat aagaaagggt ggaggtgaca agcagtgagg
aagtttaaag 11460atgcatgaaa tctgtaaagt ctcagaacaa gaattctcct
aaaatgcaaa aggggctttg 11520ctggtctccc cttggcttct catgtagctc
acctcttttt tcttatcttg agactagtca 11580aacctaagct gtttctcatt
ttatttccag aagctattga gaacactctc ctgaattctt 11640caaattcagt
agagggcgac aaatgtacat ataaatgatg gtagtgggtc ttaaataaag
11700actcatgaca cctaaagggg cagcacctga gtctgattgc acctgtttct
gttgctgttt 11760ctgtctctct tctctctgtc tgccatttca ttatcaatgg
ttactttact tataagatca 11820tattagaacc tgatatttga taaatgatgc
atcagatcta tagtgagaga aaaaattaat 11880gcaattaaag gtgttgtaac
agctagtctt caagtgggga gaaatcattt gagtacctta 11940ggtcacagct
tacatcaaaa caaaaaatca gagctacatt aaaaagtgaa attttaacta
12000tatcaaacaa tagaaaaaaa cagaagaaaa ttgaatactt actaaatctt
agcatgaata 12060agaactgttt aacacttaga ggcaaggact gggcgtggtg
gctcatgctt ttaatcccag 12120gactttggga gcccaaggcg ggcggatcac
ctgaggtcag gagtttgaga ctagcctggc 12180caacatggtg aaaccccgtc
tctactaaaa aatgcaaaaa ttagctgcgt gtggtggtgc 12240atgcctgtaa
tctcagctac ttgggaggct aaggcatgag aatcgcttga acctgggagg
12300tggaggctgt agtgagccga gattgtgcca ctgcactaca gcctgggtga
cagtgtgaaa 12360tcctctctct caaaaaaaaa aaaaaaaaaa agcaaactag
agcagtgagg taccattatt 12420tcctttgctc actaaactga caacacacaa
atgtttttta taatacccaa agctgatgag 12480ggtagttaag gtatgccctt
ttatacacac actaatgatg tactactggt tggcagtata 12540acatatgctg
ccatgtgggg atatgtatca ggagacttaa aaatgtgcat accttttggt
12600ccagtaattt acttctggga atctgtcata acagaataat aatcttgggg
aaagctacat 12660gcctaaggat atttaaaata ttatttaaaa atcaaagtat
aatttcttac agaatataaa 12720ataatatttt aaaatgaaaa tatgctaaaa
gtttgatgaa atataaatgg tcaaatatat 12780attgattata tccacttact
agactagcac tcactctgag acgttaaaaa tagtcattat 12840aaaaactaga
aaatgccaaa gacaaaataa aggaataaag ttttacataa agtatgattc
12900cactatgttt aaaaataaac agagacattc ttggagttga gtattgtttt
cttttctgtc 12960atgtccaaag aactatataa ctattatttt taatgaacta
tatatgtaat atatacatat 13020agtttatatg tatatacaaa atttatctca
tatatatgat aaagatgaaa gatgagttgg 13080atgtgccacg tgaagtgggt
agtatagaaa cccaggtaat ggggcatagg agtgggattc 13140cagataccag
gcccatgttt ttggggtgag attgccaatc acggtctttc ttccatccct
13200cacagaggag taggtttgtc ttcaacaaac cttcagttgt cctgaagaca
aacctaattc 13260tggagacttc atataatcta gaagagacaa gcaaactgat
gaaaaatagt gaatttttaa 13320ggtaaaataa agtacatgga ctacactttg
tttagaatca gattcttggg attaaccaca 13380ttaacccaca gagggtctta
gtgatgcctc taatccagga tcctaggacc tatttctctc
13440tgtgagatgc tttctcccaa ctccttggtg agagtgggaa gactaagacc
tcagcaatct 13500gaggtggagg cctaagatcc ccctaagatc ggaggcagaa
tctgagaggg gataaaagtc 13560cctatacctg tattgggccc ttttctggga
gggggatatc aaagaatgat tttgagacag 13620ggaggctttt gactacctgt
gccacttgag ctctttgcta gggctccaga atacatattt 13680caaatacatt
ccccctccct ccttccttcc ctcttccact cttccttttt atcttccttt
13740cttcttttcc ttcctccttc ccttcctttc tctggctctc tcatgatttc
ttttcctcat 13800tataaaagtg cttatttagt ccctactctg ctattagtgt
gttagtcttt gtcccctggt 13860acttgctgtt taatggagaa atgggtgagc
aaaacagaaa ttacagcaga gtgcaataat 13920agagctaagc caggtgtata
aatccattct cacactgctg taaaaaacta ctgggtaatt 13980tataaagaaa
agaggtttaa ttgactcaca gttccacagg ctgtacagga agcatggctg
14040gggaggcctc agaaaactta caatcatggt ggaagaaaga gcgaagggga
agcaagcaca 14100tcacacagca gcaggagaga gagagagaaa gagagagaga
gagaatatag gggaagtgct 14160acacactttc aaccagatct tgtgagaatt
cacctactat catgagaaca gcaagggata 14220agtctgcctc catgattcag
tcacctccta ccaggcccct tctccaacac atgtcgacgt 14280gctatttggg
tggggacaca gacccaaacc atattaccag ggcactggag aaacacagag
14340gggaaagaac cagccaagga gtgagatgga gaacaaggag gacttcttga
aacagatgac 14400atccaaactg ggtcctgaaa gctgaataga gattagacag
gggaggaggg gcagctaaag 14460atggctcagg caaacaaagg gccaggggat
atgttcatgg gatgatgtgt ctctcgttgt 14520ctgcttaaca caaggtgagt
ctctccctcc ctctctctct ctttttctct gtgtgtgttt 14580gtgtgtgtgc
atgtgtgcaa atgtaatata cccaatagtc aaacatgtgc cccaggagag
14640gggtagagga agaaagagaa tgagagagta agaaggagga atagacacag
aaaatgagag 14700agaagggggg aaagaaaaag aagaaaggag ccagaggaga
gaagctggtt agcattgaat 14760ggagcaatct gtgtcatcgt acttgggaaa
cccaaggatg gattcttggc aagtcgactc 14820ttggagcttt ccctgtgctt
ggtcctgtgc tcagacatgg gaaaattaga ggagtgtcat 14880ctgtgcaatc
actgaattca taatcttggt gaggaaagga gactacacac agggaataat
14940gctaagtatt acagatttca gggcagaaag agatcaaggt gggctgcaat
attcagaaaa 15000gtcttcctgg aaaagttgaa tacttagaaa gcagctccta
gaagtagact ctgctgagat 15060ggacggagtc ctttgtaggt cccaactggg
tgtgtgtgtg gggtctgtct ctccatggcy 15120gacagtgcac atgtggattc
cagggctcag gatgctgttg ctgggagctg ttctactgct 15180attagctctg
cccggkcatg accaggaaac cacgactcaa gggcccggag tcctgcttcc
15240cctgcccaag ggggcctgca caggttggat ggcgggcatc ccagggcatc
cgggccataa 15300tggggcccca ggccgtgatg gcagagatgg cacccctggt
gagaagggtg agaaaggaga 15360tccaggtaag aatgtttctg gcctctttca
tcacagacct cctacactga tataaactat 15420atgaagkcat tcattattaa
ctaaggccta gacacaggga gaaagcaaag cttttttatg 15480ttaaccataa
gcaacctgar gtgatttggg gttggtcttc caaggatgag tgtagatggt
15540gcctctataa ccaagacttt ggctttgctg catctgcagc tccttttcca
tcccctttcc 15600catcttcacc ctcatcccta ttcccagtac attcatattc
tgattcctct ttctgtctgc 15660ttaacttcca tttcacccag tggcattcaa
ccacatttac tgcacacccc ctgaaaggct 15720cagtcctgcc tttggggaac
tcttgatcta ggtaagatgt ctaatgtgca aggctctgtt 15780ggtggttacc
acaagaaagt ctactctaaa aatgtcaaac tgaatgtgaa caagtattca
15840aagtatggag catagagaaa atrtactcac cgtggacctg atgaagaatg
aaggcttcaa 15900ggaggaggca gagcttcagc taggccttga atgatgggta
ggcagaatag aggaggagag 15960acatcctaga tggagggggt agaattgcaa
aaccagggtt gatggtgcca gcacataaag 16020ggctggcagg gtggagggtc
tatgatagag acctatagga gataaagata gagttgaaat 16080tatgggagcc
tccatgtctg tgggagatat agaaggagga ggtaacacct ctctcctttt
16140gggagctctt attggtttct tgatctataa gtcaagaagg ttgtgagtgg
gagccacagg 16200gatggtaatt taggctgtaa ccaacctagg caggagttct
gttctttgta gtcactgagg 16260tcttctcatt ccttaggtct tattggtcct
aagggagaca tcggtgaaac cggagtaccc 16320ggggctgaag gtccccgagg
ctttccggga atccaaggca ggaaaggaga acctggagaa 16380ggtgcctatg
tataccgctc agcattcagt gtgggattgg agacttacgt tactatcccc
16440aacatgccca ttcgctttac caagatcttc tacaatcagc aaaaccacta
tgatggctcc 16500actggtaaat tccactgcaa cattcctggg ctgtactact
ttgcctacca catcacagtc 16560tatatgaagg atgtgaaggt cagcctcttc
aagaaggaca aggctatgct cttcacctat 16620gatcagtacc aggaaaataa
tgtggaccag gcctccggct ctgtgctcct gcatctggag 16680gtgggcgacc
aagtctggct ccaggtgtat ggggaaggag agcgtaatgg actctatgct
16740gataatgaca atgactccac cttcacaggc tttcttctct accatgacac
caactgatca 16800ccactaactc agagcctcct ccaggccaaa cagccccaaa
gtcaattaaa ggctttcagt 16860acggttagga agttgattat tatttagttg
gaggccttta gatattattc attcatttac 16920tcattcattt attcattcat
tcatcaagta actttaaaaa aatcatatgc tatgttccca 16980gtcctgggga
gcttcacaaa catgaccaga taactgacta gaaagaagta gttgacagtg
17040ctattttgtg cccactgtct ctcctgatgc tcatatcaat cctataaggc
acagggaaca 17100agcattctcc tgtttttaca gattgtatcc tgaggctgag
agagttaagt gaatgtctaa 17160ggtcacacaa gtattaagtg acagtgctag
aaatcaaacc cagagctgtg gactttgttc 17220actagactgt gcccttttat
agaggtacat gttctctttg gagtgttggt aggtgtctgt 17280ttcccacctc
acctgagagc cattgaattt gccttcctca tgaattaaaa cctcccccaa
17340gcagagcttc ctcagagaaa gtggttctat gatgaagtcc tgtcttggaa
ggactactac 17400tcaatggccc ctgcactact ctacttcctc ttacctatgt
cccttctcat gcctttccct 17460ccaacgggga aagccaactc catctctaag
tgctgaactc atccctgttc ctcaaggcca 17520cctggccagg agcttctctg
atgtgatatc cacttttttt tttttttgag atggagtctc 17580actctgtcac
ccaggctgga gtacagtgac acgacctcgg ctcactgcag cctccttctc
17640ctgggtccaa gcaattattg tgcctcagcc tcccgagtag ctgagacttc
aggtgcattc 17700caccacacat ggctaatttt tgtattttta gtagaaatgg
ggtttcgtca tgttggccag 17760gctggtctcg aactcctggc ctaggtgatc
cacccgcctc gacctcccaa agtgctggga 17820ttacaggcat gagccaccat
gcccagtcga tatctcactt tttattttgc catggatgag 17880agtcctgggt
gtgaggaaca cctcccacca ggctagaggc aactgcccag gaaggactgt
17940gcttccgtca cctctaaatc ccttgcagat ccttgataaa tgcctcatga
agaccaatct 18000cttgaatccc gtatctaccc agaattaact ccattccagt
ctctgcatgt aatcagtttt 18060atccacagaa acattttcat tttaggaaat
ccctggtttt aagtatcaat ccttgttcag 18120ctggacaata tgaatctttt
ccactgaagt tagggatgac tgtgattttc agaacacgtc 18180cagaattttt
catcaagaag gtagcttgag cctgaaatgc aaaacccatg gaggaattct
18240gaagccattg tctccttgag taccaacagg gtcagggaag actgggcctc
ctgaatttat 18300tattgttctt taagaattac aggttgaggt agttgatggt
ggtaaacatt ctctcaggag 18360acaataactc cagtgatgtt cttcaaagat
tttagcaaaa acagagtaaa tagcattctc 18420tatcaatata taaatttaaa
aaactatctt tttgcttaca gttttaaatc ctgaacaatt 18480ctctcttaca
tgtgtattgc taatcattaa ggtattattt tttccacata taaagctttg
18540tctttttgtt gttgttgttg tttttaagat ggagtttccc tctgttgcca
ggctagagtg 18600cagtggcatg atctcggctt actgcaacct ttgcctccca
ggttcaagcg attcttctgc 18660ctcagcctcc cgagtagctg ggaccacagg
tgcctaccac catgccaggc taatttttgt 18720atttttagta aagacagggt
ttcaccatat tggccaggct ggtctcgaac tcctgacctt 18780gtgatctgcc
cacctccatt tttgttgtta ttttttgaga aagatagata tgaggtttag
18840agagggatga agaggtgaga gtaagccttg tgttagtcag aactctgtgt
tgtgaatgtc 18900attcacaaca gaaaacccaa aatattatgc aaactactgt
aagcaagaaa aataaaggaa 18960aaatggaaac atttattcct ttgcataata
gaaattacca gagttgttct gtctttagat 19020aaggtttgaa ccaaagctca
aaacaatcaa gacccttttc tgtatgtcct tctgttctgc 19080cttccgcagt
gtaggcttta ccctcaggtg ctacacagta tagttctagg gtttccctcc
19140cgatatcaaa aagactgtgg cctgcccagc tctcgtatcc ccaagccaca
ccatctggct 19200aaatggacat catgttttct ggtgatgccc aaagaggaga
gaggaagctc tctttcccag 19260atgccccagc aagtgtaacc ttgcatctca
ttgctctggc tgagttgtgt gcctgtttct 19320gaccaatcac tgagtcagga
ggatgaaata ttcatattga cttaattgca gcttaagtta 19380ggggtatgta
gaggtatttt ccctaaagca aaattgggac actgttatca gaaataggag
19440agtggatgat agatgcaaaa taatacctgt ccacaacaaa ctcttaatgc
tgtgtttgag 19500ctttcatgag tttcccagag agacatagct ggaaaattcc
tattgatttt ctctaaaatt 19560tcaacaagta gctaaagtct ggctatgctc
acagtctcac atctggttgg ggtgggctcc 19620ttacagaaca cgctttcaca
gttaccctaa actctctggg gcagggttat tcctttgtgg 19680aaccagaggc
acagagagag tcaactgagg ccaaaagagg cctgagagaa actgaggtca
19740agatttcagg attaatggtc ctgtgatgct ttgaagtaca attgtggatt
tgtccaattc 19800tctttagttc tgtcagcttt tgcttcatat attttagcgc
tctattatta gatatataca 19860tgtttagtat tatgtcttat tggtgcattt
actctcttat cattatgtaa tgtccttctt 19920tatctgtgat aattttctgt
gttctgaagt ctactttgtc taaaaataac atacgcactc 19980aacttccttt
tctttcttcc ttcctttctt tcttccttcc tttctttctc tctctctctc
20040tttccttcct tccttcctcc ttttctttct ctctctctct ctctctcttt
ttttgacaga 20100ctctcgttct gtggccctgg ctggagttca gtggtgtgat
cttggctcac tgctacctct 20160accatgagca attctcctgc ctcagcctcc
caagtagctg gaactacagg ctcatgccac 20220tgcgcccagc taatttttgt
atttttcgta gagacggggt ttcaccacat tcgtcaggtt 20280ggtttcaaac
tcctgacttt gtgatccacc cgcctcggcc tcccaaagtg ctgggattac
20340aggcatgagc catcacacct ggtcaacttt cttttgatta gtgtttttgt
ggtatatctt 20400tttccatcat gttactttaa atatatctat attattgtat
ttaaaatgtg tttcttacag 20460actgcatgta gttgggtata atttttatcc
agtctaaaaa tatctgtctt ttaattggtg 20520tttagacaat ttatatttaa
taaaattgtt gaatttaaga tggatgactg ttttatttgt 20580ttgctgttca
ccacttctgt tttattctct ttccagaatt cttttggatt gtttaaatat
20640ttcataatat tttatcttaa tttatttatt gggtatttgc ctatatctct
ttgtggtatt 20700ttttagtggt tgcttgaggg attacaatgt acttaacttt
tcacagtgtg cataaagtta 20760atattttgcc acttgcagta aaccgtagaa
ggcttataat catattagta cctctatcca 20820ctttctttta tgttgtagtt
gtcatatata ttacatctat atacactgaa acattatagg 20880caatgttatg
atttttgcat tcgtcagtca tatatatatt ttaaagaatt taagaggaga
20940aaaatacata ttcagatatt catcat 20966
* * * * *